program and schedule of events – schedule (pdf format)

ISPOR 3Rd ASIA-PAcIfIc cOnfeRence

7-9 September 2008 • Grand Hilton Seoul • Seoul, South Korea

Evidence-Based Health Care Decision Making In Asia-Pacific: The Application of Pharmacoeconomics and Outcomes Research

Program and Schedule of eventS

Co-organized by:iSPor asia Consortium

Seoul national University, South Korea

The Korean association of Health Technology assessment, South Korea

InternatIonal SocIety for PharmacoeconomIcS and outcomeS reSearch

Mission: ISPOR promotes the science of phar-macoeconomics (health economics) and out-comes research (the scientific discipline that evaluates the effect of health care interven-tions on patient well-being including clinical outcomes, economic outcomes, and patient-reported outcomes) and facilitates the trans-lation of this research into useful information for healthcare decision-makers to ensure that society allocates scarce health care resources wisely, fairly and efficiently.

Vision: ISPOR is a fully international, educa-tional and scientific organization that fosters excellence in the core disciplines of pharmacoeconomics (health economics) and outcomes research and the use of this research information in health care decisions at all levels.

Scope: ISPOR embraces health care researchers from all disciplines conducting health care outcomes research. These disciplines include pharmacoeconomics (health economics), epi-demiology (pharmacoepidemiology), decision analysis, modeling, risk assessment, patient-reported outcomes (quality of life), use of ‘real world’ data such as health care database analyses, observational studies, patient regis-tries. Health care includes use of pharmaceu-ticals, biologics, genetically-derived products, medical devices, delivery systems, and health services.

Thanks to the following for providing the translations: Jinhee Lee (Korean)

Shanlian Hu MD, MSc and Wen Chen PhD (Chinese)

Isao Kamae MD, DrPH and Hiroyuki Sakamaki MBA, Dr Med Sci. (Japanese)

www.ispor.org

ispor MissioN

iNterNatioNal society for pharMacoecoNoMics aNd outcoMes research

2

3

Dear Colleagues,

On behalf of the Asia Consortium of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), I welcome you to the ISPOR 3rd Asia-Pacific Conference in Seoul, South Korea. This Conference is co-organized by the ISPOR Asia Consortium, Seoul National University, and the Korean Association for Health Technology Assessment (KAHTA), and co-sponsored by the Health Insurance Review & Assessment Service (HIRA), and the National Health Insurance Corporation (NHIC) of South Korea, as well as organizations from other Asian countries. Two years ago, the Asia Consortium began the initial planning stage of this Conference. After two years of dedicated service, we have now realized this goal. I would like to thank Dr. Bong-Min Yang, the Conference Chair, Professor of Seoul National University, and President of KAHTA, for his great leadership in the development and promotion of the Conference program.

ISPOR Asia Consortium, consisting of the Executive Committee and Advisory Committee, was formed by individuals who are interested in the science of pharmacoeconomics and outcomes research and its use in health care decisions in Asia. This was initiated in May 2004 and officially established in August 2004 by 12 founding members from China mainland, Hong Kong, Taiwan, Japan, Singapore, South Korea, Thailand, and USA. To date, through the efforts of its 32 members, the Executive Committee has extended to India, Indonesia, Malaysia, Mongolia, Pakistan, and Philippines. In addition, there are 40 Advisory Committee members from around the world. These Com-mittees work closely together to make sure that the Consortium

• provides a platform for researchers, health care practitioners, decision-makers and industry members who are interested in pharma-coeconomics and outcomes research to share knowledge and experiences at the regional level;

• encourages the use of the science of pharmacoeconomics by health care decision-makers in Asia;

• promotes the concepts of efficiency and affordability for better utilization of health care resources in different countries in Asia;

• serves as a resource and provides an opportunity for individuals to become more familiar with pharmacoeconomics and outcomes research as well as health care policies in Asia; and

• promotes the formation of country or province based ISPOR Chapters in Asia.

One of the main activities of the Consortium is to initiate and facilitate the ISPOR Asia-Pacific Conferences. After the success of the ISPOR 1st Asia-Pacific Conference in September 2003 in Kobe, Japan, the Asia Consortium had its ISPOR 2nd Asia-Pacific Conference in March 2006 in Shanghai, China. The ISPOR 4th Asia-Pacific Conference is scheduled for September 2010 in Phuket, Thailand, and the 5th in 2012 in Singapore. In addition to the Conferences, the Consortium has initiated the Value in Health Asia Special Issue published in April 2008, which contains 20 papers selected from the presentations given at the ISPOR 2nd Asia-Pacific Conference, and from original research that focuses on Asian studies of pharmacoeconomics and outcomes research. The Consortium has planned to begin work on the 2nd Value in Health Asia Special Issue after this Conference. In promoting the formation of ISPOR Chapters, the Consortium plays a significant role through its members in each country. After beginning with only 2 Chapters, the Consortium now has 7 Chapters with over 430 members. The Consortium works closely with Chapters, providing scientific support in organizing their annual conferences, or to host an educational forum, workshop, or symposium.

I would like to acknowledge the leadership of Drs. Gordon Liu, and Kenneth Lee, 2004-2006 and 2006-2008 Chairs of the Consortium Execu-tive Committee; and Drs. Hong Li and Jeff Guo, 2005-2007 and 2007-2009 Chairs of the Consortium Advisory Committee. I would also like to give my thanks to all Consortium members who have dedicated their time, energy, and expertise voluntarily to ensuring the success of initiatives. I hope that you find the Conference beneficial and a complete success!

Sincerely,

Shanlian Hu MD, MSc2008-2010 Chair, ISPOR Asia Consortium Executive CommitteeProfessor, Training Center for Health Management, School of Public Health, Fudan University, Shanghai, China

Guide to the Program and Schedule of eventsThis book is divided into the following nine sections:Section 1: Conference Overview (page 2-12)Section 2: Short Course Program (page 13-16)Section 3: Conference Program & Schedule of Events (page 17-38)Section 4: Invited Speaker Biographical Information (page 39-46)Section 5: First Plenary Session Information (page 47-50) Section 6: Issue Panel, Workshop & Symposium Descriptions (page 51-58)Section 7: Research Presentation Abstracts (page 59-117)Section 8: Exhibit Program (page 119-124)Section 9: ISPOR Leadership Directory (page 127-137)

Submission & Presentation Information• In 2008, for the ISPOR 3rd Asia-Pacific Conference, 300 abstracts/proposals were

submitted; 60 are accepted for podium presentations; 182 for poster presenta-tions; 13 for workshops; and 2 for issue panels. In addition, 5 invited workshops/issue panels and 12 short courses are provided.

• In 2006, for the ISPOR 2nd Asia-Pacific Conference held in Shanghai, China, 254 abstracts/proposals were submitted; 35 were accepted for podium presentations; 150 for poster presentations; and 17 for workshops. In addition, 9 special sessions and 9 short courses were offered.

• In 2003, for the 1st ISPOR Asia-Pacific Conference held in Kobe, Japan, 140 ab-stracts/proposals were submitted; 84 posters and 10 workshops were presented. In addition, 6 short courses were offered.

Research Podium PresentationsOutcomes research (clinical, economic, and patient-reported), health policy re-search and research on methods for the following topics will be presented as 15 minute oral presentations: Research from China: CHCancer: CNCardiovascular Disease: CVDiabetes: DBInfection: IFResearch from India: INResearch from Japan: JAResearch from South Korea: KOResearch from Thailand: THCost-Effectiveness Studies: CECost Studies: CSHealth Policy: HPResearch on Methods: MEMental Health: MHPatient-Reported Outcomes Studies: PRSee pages 60-74 for Podium Presentation Abstracts

Research Poster Presentations Poster presentations will be on view in the Grand Ballroom. Poster Display Hours:Monday, 8 September: 8:00AM - 8:00PM Tuesday, 9 September: 8.00AM - 6:00PMPoster Set-Up: Monday, 8 September: 7:00AM - 8:00AMPoster Author Discussion Hour: Monday, 8 September: 6:00PM - 7:00PMPresenters are required to be with their posters during the Poster Author Discussion HourPoster Dismantle: Tuesday, 9 September: 6:00PM – 6:30PM

Outcomes research (clinical, economic, and patient-reported), health policy research and research on methods for the following diseases/disorders/topics will be on view: Cancer: PCNCardiovascular Disorders: PCVDiabetes/Endocrine Disorders: PDB

GI Disorders: PGIHealth Policy: PHPIndividual’s Health: PIHInfection: PINConceptual Papers & Research on Methods: PMCMental Health: PMHMuscular-Skeletal Disorders: PMSNeurological Disorders: PND Respiratory-Related Disorders: PRSSensory Systems Disorders: PSSSystemic Disorders/Conditions: PSY Urinary/Kidney Disorders: PUK See pages 75-117 for Poster Presentation Abstracts

Reference Page numbersPage numbers to the left of presentation code in the program refer to the corre-sponding page for the podium/poster presentation abstracts published in this book.

Research Awards Awards are given for the Best Research Podium Presentation (up to 6) and Best Research Poster Presentation (up to 6). All research podium presenta-tions are considered for an award. Research poster presentations in the top 30%, based on abstract review score, are considered for a poster award. These are identified with a rosette. ISPOR Research Awards will be presented

immediately after Workshop Session III on Tuesday, 9 September 2008 at 5:15pm.

exhibitsExhibits will be on view in the Grand Ballroom: Monday, 8 September: 8:00am - 8:00pm Tuesday, 9 September: 8:00am - 6:00pm

Simultaneous TranslationSimultaneous translation between English and Korean is provided on Monday for the Conference Welcome Session, Guest Presentation, First Plenary Session and Second Plenary Session. Simultaneous translation is also available for two of Sunday’s sponsored educational symposia. Translated presentations are indicated with a . Conference translation services are supported by Eli Lilly.

Handouts• Handouts for Plenary Sessions, ISPOR Forums & Invited Workshops/Issue Panels

are available in the session room at the time of the presentations.• Handouts for Contributed Presentations (contributed research podiums and

posters, workshops and issue panels) are the sole responsibility of the presenting author(s). ISPOR requires all contributed presenters to provide at least 200 copies of their handouts.

• Handouts for Educational Symposia are the sole responsibility of the host organization(s).

• All Remaining & Additional Handouts will be available at the Handout Table near the ISPOR Registration Desk.

Please Note: Following the conference, subject to author’s permission, released research presentations are available in the ISPOR Research Digest (a searchable database of over 10,000 research papers presented at ISPOR’s meetings from 1998 to date at www.ispor.org)

conference Program WarningPlease be advised that recording, by any means, of Conference presentations is prohibited. The International Society for Phamacoeconomics and Outcomes Research (ISPOR) will strictly enforce its rights as the exclusive license of all publi-cation and reproduction rights to each presentation, and no presentation, in whole or in part, may be reproduced without approval from ISPOR.

ISPOR 3RD ASIA-PAcIfIc cONfeReNce 7-9 September 2008 • Seoul, South Korea

KeY InfORMATIOn

4

Dear Friends and Colleagues:

Welcome to Seoul and the 3rd Asia-Pacific Conference of the International Soci-ety for Pharmacoeconomics and Outcomes Research (ISPOR). On behalf of the Program Committee and the Conference Advisory Committee, I am very pleased to introduce to you the Conference program.

The theme of this Conference is “Evidence-Based Health Care Decision in Asia Pacific: The Application of Pharmacoeconomics and Outcomes Research”. There will be three plenary sessions, beginning with the discussion on evidence-based health care decision making in 10 Asian health systems. The 2nd and 3rd plenary sessions will examine international experience and how it can be adapted globally in focusing on developing evidence by using health technology assessment and the development and implementation of pharmacoeconomic guidelines. This Conference also features 60 podium presentations, 182 poster presentations, 13 workshops, 5 issue panels, and 12 short courses. In addition, there is a forum organized by the ISPOR Asia-Pacific Medical Device & Diagnostics Council, 6 sponsored educational symposia, and more than 10 exhibitors. On Sunday evening, 7 September, 2008, ISPOR will host a Welcome Reception and provide you with an opportunity to enjoy a traditional Korean cultural performance along with your colleagues from over 30 countries and regions.

I am extremely grateful to the Chairs of the program committees and the volunteer abstract/proposal reviewers who dedicated their time and energy to making this program possible. I would like to thank the Conference Co-Sponsors, Supporting Media, and Conference Advisory Committee for their efforts in planning and promoting this Conference. I also would like to thank the ISPOR Asia Consortium which initiated this Conference two years ago to help advance the science of pharmacoeconomics and health outcomes research in Asia. Finally, my sincere gratitude to all ISPOR staff who, carefully, successfully, and patiently, prepared and organized all the necessary communications between the parties involved. This Conference would not have been possible without their hard work and dedication.

Thank you to all of you, speakers, moderators, instructors and attendees for being a part of this Confer-ence. This is your conference! Please Enjoy!

Sincerely,

Bong-Min Yang PhDISPOR 3rd Asia-Pacific Conference Chair, and Professor of EconomicsSchool of Public Health, Seoul National UniversitySeoul, South Korea

5


SUNDAY, 7 SEPTEMBER

8:00AM-5:00PM PRE-CONFERENCE SHORT COURSES

5:00PM-6:00PM EDUCATIONAL SYMPOSIUM



8:30PM-10:30PM WELCOME RECEPTION & KOREAN TRADITIONAL CULTURAL PERFORMANCE

MONDAY, 8 SEPTEMBER

8:00AM-8:40AM WELCOME

8:40AM-9:00AM GUEST PRESENTATION

9:00AM-9:15AM BREAK, EXHIBIT & RESEARCH POSTER PRESENTATION VIEWING

9:15AM-11:15AM FIRST PLENARY SESSION

11:15AM-11:30AM BREAK, EXHIBIT & RESEARCH POSTER PRESENTATION VIEWING

11:30AM-12:30PM RESEARCH PODIUM PRESENTATIONS - SESSION I

12:30PM-2:00PM LUNCH, EXHIBIT & RESEARCH POSTER PRESENTATION VIEWING


2:00PM-3:00PM WORKSHOPS - SESSION I W1 W2 W3 W4

3:00PM-3:15PM BREAK, EXHIBIT & RESEARCH POSTER PRESENTATION VIEWING

3:15PM-4:15PM ISSUE PANELS IP1 IP2 IP3 IP4 IP5

4:15PM-4:30PM BREAK, EXHIBIT & RESEARCH POSTER PRESENTATION VIEWING

4:30PM-6:00PM SECOND PLENARY SESSION

6:00PM-7:00PM RESEARCH POSTER AUTHOR DISCUSSION HOUR

6:00PM-8:00PM RECEPTION, EXHIBIT & RESEARCH POSTER PRESENTATION VIEWING


schedule at-a-glance

10

Reg

ISTR

ATIO

N

7AM

-5PM

Reg

ISTR

ATIO

N 7

AM

-5PM

ExH

IBIT

S &

PO

STER

PRE

SEN

TATI

ON

S 8A

M-8

PM


TUESDAY, 9 SEPTEMBER

7:00AM-8:45AM ISPOR ASIA-PACIFIC MEDICAL DEVICE & DIAGNOSTICS COUNCIL FORUM

8:00AM-9:00AM EXHIBIT & RESEARCH POSTER PRESENTATION VIEWING

9:00AM-9:15AM WELCOME

9:15AM-10:45AM THIRD PLENARY SESSION

10:45AM-11:00AM BREAK, EXHIBITS &Research Poster Presentations VIEWING

11:00AM-12:00PM RESEARCH PODIUM PRESENTATIONS-SESSION II

12:00PM-1:30PM LUNCH, EXHIBITS &Research Poster Presentations VIEWING


1:30PM-2:30PM WORKSHOPS-SESSION II W6 W7 W8 W9 W10

2:30PM-2:45PM BREAK, EXHIBITS ANDResearch Poster Presentations VIEWING

2:45PM-3:45PM RESEARCH PODIUM PRESENTATIONS-SESSION III

3:45PM-4:00PM BREAK, EXHIBITS &Research Poster Presentations VIEWING

4:00PM-5:00PM WORKSHOPS - SESSION III W11 W12 W14 W15

5:00PM-5:15PM BREAK, EXHIBITS ANDResearch Poster Presentations VIEWING

5:15PM-6:00PM ISPOR RESEARCH AWARDS PRESENTATION ISPOR 4th ASIA-PACIFIC CONFERENCE ANNOUNCEMENT CLOSING REMARKS

schedule at-a-glance

11

Reg

ISTR

ATIO

N 7

AM

-5PM

ExH

IBIT

S &

PO

STER

PRE

SEN

TATI

ON

S 8A

M-6

PM


cOnfeRence ROOM flOOR PlAn

12


7-9 September 2008 • Seoul, South Korea

Short CourSeProgram

13


SUNDAY, 7 SEPTEMBER 2008 / 8:00AM-12:00PM MoRNiNg CoURSES

Introduction to Quality of life Assessment/Patient-Reported Outcomes White Heronbruce Crawford ma, mPH, General Manager, Asia, Mapi Values, Tokyo, Japan; Watcharee leurmarnkul Phd, Senior Research Pharmacist, Asia Pacific Department, Family Health International, Bangkok, Thailand

Course description: Definitions and concepts, methodologies, and practical methods for measuring patient-reported outcomes will be presented. The value of patient-reported outcomes assessment will be discussed. A strategy to aid in selecting appropriate instruments and the translation processes will be presented. Instrument development and validation will be discussed using practical examples and exercises. Designed for indi-viduals with little experience with quality of life/PRO studies.

Introduction to decision Analysis SkylarkShu-Chuen li Phd, mS, mba, Professor, Chair & Head, Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences, University of Newcastle, Callaghan, NSW, Australia, and Visiting Professor Department of Pharmacy, National University of Singapore, Singapore, Singapore

Course description: Participants will learn to evaluate the appropriateness of decision analysis in different settings, construct simple decision trees, understand the basic mechanics of tree evaluation and sensitivity analysis, and acquire skills in the interpretation of a published decision analysis. Suitable for those with little experience with decision analysis.

Meta-Analysis and Systematic literature Review Flamingonathorn Chaiyakunapruk Pharmd, Phd, Associate Professor, School of Pharmacy, Naresuan University, Phitsanulok, Thailand; Seokyung Hahn Phd, Assistant Professor of Medical Statistics, Medical Research Collaborating Center, Seoul National University, Seoul, South Korea

Course description: This course highlights and expounds upon four key areas: 1) impetus for meta-analysis and systematic reviews, 2) basic steps to perform a quantitative systematic review, 3) statistical methods of combining data, and 4) appraisal and use of meta-analytic reports. Designed for those with little experience with meta-analysis.

Introduction to Biostatistics in clinical Trials and economic Studies Swanisao Kamae md, Phd, Professor and Chair, Graduate School of Health Management, Keio University, Tokyo, Japan; guk-Hee Suh md, Phd, Professor of Psychiatry, Hallym University Medical Center, Hangang Sacred Heart Hospital, Seoul, South Korea; alan J.m. brnabic ma, Statistics Manager, Intercontinental Information Sciences (ICIS), Eli Lilly Australia Pty Limited, West Ryde, NSW, Australia

Course description: Providing an introduction to biostatistics and pharmacoeconomics analysis in clinical trials, the course will include elementary probability theory, basic concepts of statistical inference, sampling theory, hypothesis tests for randomized controlled trials, etc. Designed to familiarize new researchers or managers interested in research with current statistical techniques.

Pharmacoeconomics for Health care decision-makers CraneKenneth KC lee JP, bSc(Pharm), mPhil, Phd, Professor and Associate Director (External Affairs), School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, China, and Visiting Professor, University of London School of Pharmacy, London, UK

Course description: Participants will learn the basic concepts and tools for conducting pharmacoeconomics and outcomes research. Different assessment methods including cost-effectiveness, cost-minimization, cost of illness, cost-utility and cost-benefit analysis will be discussed. The applications of PE and OR data will be covered and illustrated by practical examples. Designed to assist decision-making for health care workers with limited knowledge and experience of pharma-coeconomics and outcomes research.

short courses

B. Crawford W. Leurmarnkul

S. Li

N. Chaiyakunapruk S. Hahn

I. Kamae G. Suh A. Brnabic

K. Lee

14


formulary development Board RoomKenneth Hartigan-go Phd, Executive Director, The Zuellig Foundation, Makati City, Philippines; you-meei lin, Assistant Director, Department of Pharmacy, Taipei Medical University - Wan Fang Hospital, Taipei, Taiwan

Course description: This course will describe the organizational structure of the Pharmacy & Therapeutics committee, the new drug application and review procedures, the preparation of drug monographs and description of the one-in and one-out process with a discussion of the evidence-based practices with pharmacoeconomic consider-ation put into practice, the enforcement of drug formulary, etc. Designed for those with little experience in developing a formulary.

SUNDAY, 7 SEPTEMBER 2008 / 1:00PM-5:00PM AfTERNooN CoURSES

Budget Impact and cost Analysis Flamingogordon g. liu Phd, Professor and Chair, Department of Health Economics and Management, Guanghua School of Management, Peking University, Beijing, China

Course description: This course will describe methods to determine the cost-of-illness of a health condition. Participants will learn how to estimate the impact of new health care technologies on disease-specific costs from different decision-maker perspectives. Actuarial methods using straight-line projections and nonlinear trends will be described. Designed for those with some experience with pharmacoeconomic analysis.

Retrospective data Analysis SkylarkJeff J. guo, Phd, Associate Professor, James L. Winkle College of Pharmacy, Faculty Research Fellow, Institute for Health Policy and Health Service Research, University of Cincinnati Medical Center, Cincinnati, OH, USA; eui-Kyung lee Phd, Professor, Graduate School of Clinical Pharmacy, Sookmyung University, Seoul, South Korea

Course description: Large administrative claims databases provide a unique opportunity to examine retrospectively the effects of drug use on clinical and economic outcomes in the “real world” settings. Retrospective data analysis, such as data from medical claims or the other health databases will be discussed. The advantages and disadvantages of using these datasets to perform economic analyses and epidemiologic studies will be outlined. Designed for those with little experience with database analysis.

elements of Pharmaceutical/Biotech Pricing Board RoomWayne Critchley, Partner, Gowling Lafleur Henderson LLP, Ottawa, ON, Canada; Jack mycka, President and Partner, MME LLC, Montclair, NJ, USA; manny Papadimitropoulos Phd, Director, Health Outcomes Research, Intercontinental Region and Japan, Eli Lilly Canada Inc., Toronto, ON, Canada and Assistant Professor, Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada

Course description: This course will give participants a basic understanding of the key terminology and issues involved in pharma-ceutical pricing decisions. It will cover the tools to build and document product value including issues, information and processes employed; the role of pharmacoeconomics and the differences in payment systems that help to shape pricing decisions. These tools will be further explored through a series of interactive exercises. Designed for those with limited experience in the area of pharmaceutical pricing, topics will be covered within a global context.

Pharmacoeconomic Guidelines for Health care decision-makers SwanShanlian Hu md, Professor, Training Center for Health Management, School of Public Health, Fudan University, Shanghai, China; Tony yen-Huei Tarn Phd, Senior Researcher, Health Technology Assessment Task Force, Center for Drug Evaluation, Taipei, Taiwan

Course description: Participants will learn the main contents and analytic techniques in pharmacoeconomic guidelines, the differ-ences between pharmacoeconomic guidelines around the world and some country-specific pharmacoeconomic guidelines, and the political and technical process of its formulation and implementation. Designed to teach researchers, clinicians, drug manufacturers and policy makers how to use pharmacoeconomic guidelines from an international perspective.

G. Liu

J. Guo E.K. Lee

W. Critchley J. Mycka M. Papadimitropoulos

K. Hartigan-Go Y. Lin

S. Hu Y. T. Tarn

15


SUNDAY, 7 SEPTEMBER 2008 / 1:00PM-5:00PM AfTERNooN CoURSES continued...

Reimbursement System and Methodologies White Heronmadeleine r. Valera md, Senior Vice President for Health Finance Policy and Services Sector, Philippine Health Insurance Corporation, Pasig City, Philippines; eduardo banzon md, Senior Health Specialist, World Bank-Manila Office, Pasig City, Philippines; Christian gericke, md, Professor and Chair in Public Health Policy, The University of Adelaide, Adelaide, Australia, and Honorary Senior Fellow, European Observatory on Health Systems and Policies

Course description: This course is designed to provide the participants with an understanding of the basic principles of reim-bursement systems and methodologies. Recent pharmaceutical spending patterns, trends and cost-containment measures will be discussed taking account of the wider policy context. Designed for those with little experience in pharmaceutical pricing and reimbursement.

Applied Modeling Using decision Analysis Software TreeAge Pro CraneShu-Chuen li Phd, mS, mba, Professor, Chair & Head, Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences, University of Newcastle, Callaghan, NSW, Australia; noriaki aoki md, Phd, mS, mba, Assistant Professor, School of Health Information Sciences, The University of Texas Health Science Center at Houston, TX, USA, & President of Center for Health Service, Outcomes Research and Development - Japan (CHORD-J), Tokyo, Japan

Course description: This course is a hands-on introduction to the use of software in the creation and analysis of cost-effectiveness decision models. The basic techniques for decision tree modeling, simple Markov modeling and Monte Carlo simulation will be introduced. Useful techniques to manage variables and tables in the TreeAge Pro, and to develop Excel dashboard with be demon-strated. This course requires basic understanding of decision analysis. All participants must bring a Windows laptop computer. A copy of TreeAge Pro Suite will be provided at the beginning of the course.

S. Li N. Aoki

M. Valera E. Banzon C. Gericke

16


7-9 September 2008 • Seoul, South Korea

Program aND

SCheDuLe oF eVeNtS

17

SUNDAY, 7 SEPTEMBER 2008

8:00AM-5:00PM PRE-CONFERENCE SHORT COURSES (See page 13 for Short Course descriptions)

5:00PM-6:00PM EDUCATIONAL SYMPOSIUM (Sponsored by Novartis) Convention Hall DE Key Principles for Health Technology assessment: Turning Principles into Practice (See page 57-58 for Symposium descriptions)

6:15PM-7:15PM EDUCATIONAL SYMPOSIUM (Sponsored by Wyeth) Convention Hall DE biologics in asia-Pacific - new Frontiers in Health Technology assessment Simultaneous English/Korean translation provided (See page 57-58 for Symposium descriptions)

7:30PM-8:30PM EDUCATIONAL SYMPOSIUM (Sponsored by Pfizer) Convention Hall DE Turn right or left? – China Health Care reform at a Crossroad Presented in Chinese with simultaneous Korean and English translation (See page 57-58 for Symposium descriptions)

8:30PM-10:30PM WELCOME RECEPTION WITH KOREAN TRADITIONAL CULTURAL PERFORMANCE Convention Hall BC Reception supported by Novartis Korean Traditional Cultural Performance supported by Hanmi Pharmaceutical Company

MoNDAY, 8 SEPTEMBER 2008

8:00AM-8:40AM WELCOME Convention Hall DE Simultaneous English/Korean translation provided Bong-Min Yang PhD, Program Chair, and Professor, School of Public Health, Seoul National University, Seoul, South Korea Jang-Moo Lee BS, PhD, President, Seoul National University, Seoul, South Korea Chris L. Pashos PhD, 2008-2009 ISPOR President and Vice President & Executive Director of HERQuLES Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA Shanlian Hu MD, MSc, 2008-1010 Consortium Executive Committee Chair and Professor, School of Public Health, Fudan University, Shanghai, China (See page 39 for biographical information)

8:40AM-9:00AM GUEST PRESENTATION Convention Hall DE Simultaneous English/Korean translation provided President, Health Insurance Review & Assessment Service (HIRA), Seoul, South Korea

9:00AM-9:15AM BREAK, EXHIBIT & RESEARCH POSTER PRESENTATION VIEWING Grand Ballroom (See page 27 for poster presentations)

9:15AM-11:15AM FIRST PLENARY SESSION Convention Hall DE (See page 47 for first plenary session information)

eVidenCe-baSed deCiSion maKing in aSia-PaCiFiC HealTH Care SySTemS oF CHina mainland, india, JaPan, SoUTH Korea, malaySia, PaKiSTan, PHiliPPineS, SingaPore, TaiWan and THailand

Simultaneous English/Korean translation provided (See page 39 for biographical information) A panel discussion on evidence-based health care decision making in the health care systems of the listed countries/areas. The

discussion will focus on health technology approval, pricing, reimbursement and financial control policies (drug, medical device & diagnostics). Moderator: Kenneth KC Lee JP, BSc(Pharm), MPhil, PhD, Professor and Associate Director (External Affairs), School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, China, and Visiting Professor, University of London School of Pharmacy, London, UK

Rapidly Changing Systems: Thailand, South Korea and Taiwan Panelists: Suwit Wibulpolprasert PhD, Senior Advisor on Disease Control, Ministry of Health, Nonthaburi, Thailand Tae-Jin Lee PhD, Associate Professor of Health Economics, School of Public Health, Seoul National University, Seoul, South Korea Ming-Chin Yang PhD, Associate Professor, Medical Administration Institute, National Taiwan University, Taipei, Taiwan Moderately Changing Systems: China Mainland, Japan and Singapore Panelists: Gordon G. Liu PhD, Professor and Chair, Department of Health Economics and Management, Guanghua School of Management, Peking University, Beijing, China

Takashi Fukuda PhD, Associate Professor, Department of Health Economics and Epidemiology Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Chien Earn Lee PhD, Senior Director, Healthcare Performance Group, Ministry of Health, Singapore, Singapore


schedule of events

B. Yang J. Lee

C. Pashos S. Hu

K. Lee

18


Gradually Changing Systems: India, Pakistan, Malaysia and Philippines Panelists: Urmila Mukund Thatte PhD, DNB, MD, MBBS, Professor and Head, Department of Clinical Pharmacology, Topiwala National Medical College, and BYL Nair Charitable Hospital Mumbai Central, Mumbai, India Muhammad Ashar Malik MSc, Senior Instructor, Department of Community Health Sciences, Faculty of Health Sciences, Medical College, The Aga Khan University, Karachi, Pakistan

Samsinah Hussain PhD, Associate Professor, Head of Department of Pharmacy, University of Malaya, Member of the Drug Control Authority (DCA) and Phar-macy Board, Ministry of Health, Kuala Lumpur, Malaysia Madeleine R. Valera MD, MScIH (Heidelberg), Senior Vice President for Health Finance Policy and Services Sector, Philippine Health Insurance Corporation, Pasig City, Philippines

Respondents: Sandeep Duttagupta PhD, Senior Director, Global Outcomes Research, Japan /Asia & Canada-Latin America-Africa-Middle East, Pfizer Inc., New York, NY, USA Sheldon Kong PhD, Head, Global Outcomes Research, Merck & Company, Inc., Whitehouse Station, NJ, USA

Hong Li PhD, MPH, Group Director, Outcomes Research - Asia Pacific, Department of Global Epidemiology and Outcomes Research, Bristol-Myers Squibb Company, Singapore, Singapore Mingliang Zhang PhD, Senior Director, Worldwide Health Economics and Pricing, Johnson and Johnson Pharmaceutical Services, Raritan, NJ, USA

11:15AM-11:30AM BREAK, EXHIBIT & RESEARCH POSTER PRESENTATION VIEWING Grand Ballroom (See page 27 for poster presentations)

11:30AM-12:30PM RESEARCH PODIUM PRESENTATIONS – SESSION I (Page numbers shown to the left refer to the abstract in this Program & Schedule of Events)

Research from china SwanModerator: Shanlian Hu MD, MSc, Professor, Training Center for Health Management, School of Public Health, Fudan University, Shanghai, China pg 60 CH1 BURDEN OF DIABETES IN CHINA Jing L1, Hu S2, 1Novo Nordisk (China) Pharmaceuticals Co. Ltd, Beijing, China, 2Fudan University, Shanghai, China pg 60 CH2 THE SMOKING EFFECTS ON THE ELDERLY IN CHINA Li L1, Chen Q1, Jiang Y2, Jia R3, 1Peking University, Beijing, China, 2Peiking University, Beijing, China, 3Stockholm University, Stockholm, Sweden pg 60 CH3 ECONOMIC BURDEN OF SMOKING IN CHINA Li L1, Chen Q1, Cui X1, Yu J1, Jia R2, 1Peking University, Beijing, China, 2Stockholm University, Stockholm, Sweden pg 60 CH4 ECONOMIC EVALUATION OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE BREAST CANCER chen W, Huang Y, Qiao N, Fudan University, Shanghai, China

Research from India CraneModerator: Urmila Mukund Thatte PhD, DNB, MD, MBBS, Professor and Head, Department of Clinical Pharmacology, Topiwala National Medical College, BYL Nair Charitable Hospital Mumbai Central, Mumbai, Indiapg 60 IN1 cOST ANALYSIS Of TReATINg AcUTe MYOcARDIAL INfARcTION IN INDIA Kochhar P1, Suvarna V1, Duttagupta S2, 1Pfizer India, Mumbai, India, 2Pfizer Inc, New York, NY, USA pg 61 IN2 EVALUATION OF CURRENT TREATMENT PRACTICES AND OUTCOMES FOR PATIENTS WITH TYPE 2 DIABETES: PROFILE OF UNCONTROLLED DIABETES PATIENTS

TReATeD IN A PRIVATe cLINIc IN INDIA Morarka A, Davis S, Kochhar P, Suvarna V, Pfizer India, Mumbai, India pg 61 IN3 BURDEN OF NEUROPATHIC PAIN IN INDIAN PATIENTS ATTENDING URBAN, SPECIALTY CLINICS: RESULTS FROM A CROSS SECTIONAL STUDY Sule N, Kochhar P, Pfizer India, Mumbai, Indiapg 61 IN4 AVAILABILITY AND PRICE OF TWO INHALATION MEDICINES FOR TREATMENT OF ASTHMA IN DIFFERENT STATES OF INDIA Kotwani A, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India

S. Wibulpolprasert T. Lee M. Yang G. Liu T. Fukuda C. Lee U. Thatte M. Malik S. Hussain M. Valera

S. Duttagupta S. Kong H. Li M. Zhang

Schedule of eventS - monday, 8 September

19


Research from Japan White HeronModerator: Lillian Yu-Jen Wang MS, Market Access Manager, Novartis (Taiwan) Co., Ltd., and Executive Secretary, Taiwan Society for Pharmacoeconomics and Outcomes Research (TASPOR), Taipei, Taiwanpg 61 JA1 COST-UTILITY ANALYSIS OF SMOKING CESSATION THERAPY UNDER NATIONAL HEALTH INSURANCE SYSTEM IN JAPAN Igarashi A, Fukuda T, Tsutani K, The University of Tokyo, Bunkyo, Tokyo, Japan pg 62 JA2 ASSESSING ITEMS ON THE SF-8 JAPANESE VERSION FOR THE HEALTH-RELATED QUALITY OF LIFE: A PSYCHOMETRIC ANALYSIS BASED ON THE NOMINAL

cATegORIeS MODeL Of ITeM ReSPONSe THeORY Tokuda Y1, Okubo T2, Ohde S1, Jacobs J3, Takahashi O1, Omata F3, Hinohara S1, Fukui T1, 1St. Luke’s Life Science Institute, Chuo, Tokyo, Japan, 2Japan Society for the

Promotion of Science, Chiyoda City, Tokyo, Japan, 3St. Luke’s Life Science Institute, Chuo City, Tokyo, Japan pg 62 JA3 cOST-effecTIVeNeSS ANALYSIS Of ScReeNINg fOR IRON-DefIcIeNcY ANeMIA IN MIDDLe-AgeD WOMeN IN JAPAN Sakai M, Shimbo T, Takahashi Y, Research Institute, International Medical Center of Japan, Shinjyuku-ku, Tokyo, Japan pg 62 JA4 SAFETY OF OSELTAMIVIR (TAMIFLU®) AS MEASURED BY INCIDENCE OF INJURIES Okamoto e, National Institute of Public Health, Wako-shi, SAITAMA, Japan

Research from South Korea FlamingoModerator: Sang-Il Lee MD, PhD, MPH, Professor, Department of Preventive Medicine, College of Medicine, University of Ulsan, Seoul, South Koreapg 62 KO1 COST-BENEFIT ANALYSIS OF UNIVERSAL ROTAVIRUS VACCINATION IN KOREA Sung Y, Health Insurance Review and Assesment, Seoul, South Korea pg 63 KO2 HeALTH-ReLATeD QUALITY Of LIfe Of cOMMUNITY DWeLLeRS WITH MAJOR cHRONIc DISeASeS Kang E, Korea Institute for Health and Social Affairs, Seoul, South Koreapg 63 KO3 HEALTH STATE UTILITY ASSESSMENT BY EQ5D IN CHRONIC HEPATITIS B PATIENTS IN KOREA Lee YR1, Kwon SY2, Lee YS3, Lee JH4, Choi HM1, Lee CH2, 1GlaxoSmithKline, Seoul, South Korea, 2Konkuk University, Seoul, South Korea, 3Catholic University of Korea,

Bucheon, South Korea, 4Sungkyunkwan University, Seoul, South Korea pg 63 KO4 EVALUATION OF COST-EFFECTIVENESS OF SMOKING CESSATION INTERVENTIONS IN KOREA Bae JY1, Song HJ1, Joe KH2, Kim CH3, Song HR3, Ryu GC4, Kim DJ5, Lee EK1, 1Sook Myung Women’s University, Seoul, South Korea, 2Department of Medicine, EulJi

University, Seoul, South Korea, 3Family Medicine of Seoul Paik Hospital, seoul, South Korea, 4Korea Institute for Health and Social Affairs, Seoul, South Korea, 5The Catholic University of Korea, Holy Family Hospital, Seoul, South Korea

Research from Thailand SkylarkModerator: Nathorn Chaiyakunapruk PharmD, PhD, Associate Professor, Department of Pharmacy Practice, School of Pharmacy, Naresuan University, Phitsanulok, Thailandpg 63 TH1 BUDGET IMPACT ANALYSIS OF COMPULSORY LICENSING POLICY IMPLIMENTATION ON FOUR CANCER DRUGS IN THAILAND Mohara A, Praditsitthikorn N, Kingkaew P, Werayingyong P, Pattanaphesaj J, Yamabhai I, Teerawattananon Y, Health Intervention and Technology Assessment

Program (HITAP), Nonthaburi, Thailand pg 63 TH2 ECONOMIC COSTS OF ALCOHOL ABUSE IN THAILAND: COST OF LAW ENFORCEMENT AND CRIMINAL JUSTICE Yothasamut J, Thavorncharoensap M, Teerawattananon Y, Lertpitakpong C, Thitiboonsuwan K, Health Intervention and Technology Assessment Program (HITAP),

Nonthaburi, Thailand pg 64 TH3 COST-UTILITY ANALYSIS OF RECOMBINANT HUMAN ERYTHROPOIETIN IN CANCER PATIENTS WITH ANEMIA INDUCED BY CHEMOTHERAPY IN THAILAND Roungrong J1, Teerawattananon Y1, chaikledkaew U2, 1Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand, 2Faculty of Phar-

macy Mahidol University, Ratchathewi, Bangkok, Thailand pg 64 TH4 cOST-effecTIVeNeSS ANALYSIS Of SHIgeLLA VAccINe fOR cHILDReN UNDeR 5 YeARS OLD IN THAILAND Sribundit N1, Riewpaiboon A2, Chaikledkaew U2, Noksakda N3, 1Silpakorn University, Muang, Nakornpatom, Thailand, 2Faculty of Pharmacy Mahidol University,

Ratchathewi, Bangkok, Thailand, 3Udon Thani Province Health Office, Udon Thani, Thailand

12:30PM-2:00PM LUNCH, EXHIBIT & RESEARCH POSTER PRESENTATION VIEWING Grand Ballroom (See page 75 for poster presentations)

Lunch supported by Bristol Myers Squibb

1:00PM-2:00PM EDUCATIONAL SYMPOSIUM (Sponsored by Eli Lilly) Convention Hall DE The Use of economic models in diabetes (See page 57-58 for Symposium descriptions)

2:00PM-3:00PM WORKSHOPS - SESSION I (See page 53 for Workshop descriptions)

cLINIcAL OUTcOMeS ReSeARcHW1: META-ANALYSIS METHODS THAT ALLOW FOR COMPARISON OF INTERVENTIONS IN THE ABSENCE OF HEAD-TO-HEAD DATA Swan Discussion Leaders: Bruce Crawford MA, MPH, General Manager, Asia, Mapi Values, Tokyo, Meguro, Japan; Jeroen P Jansen PhD, Project Manager, Mapi Values,

Houten, The Netherlands

ecONOMIc OUTcOMeS ReSeARcHW2: USINg LATeNT cLASS ANALYSIS IN HeALTH OUTcOMeS ReSeARcH Skylark Discussion Leader: Jeonghoon Ahn PhD, Assistant Professor, University of Southern California, Los Angeles, CA, USA

HeALTH cARe POLIcY DeVeLOPMeNT USINg OUTcOMeS ReSeARcHW3: BURDEN OF ILLNESS STUDY FOR DEVELOPING HEALTH POLICY IN ASIA-PACIFIC White Heron Discussion Leaders: Bong-Min Yang PhD, Professor, School of Public Health, Seoul National University, Seoul, South Korea; Q. Chau Tini Nguyen PharmD, AP Direc-

tor, Sanofi-Aventis, Paris, France; Shu-Chuen Li Ph, D/MBA, Associate Professor, National University of Singapore, Singapore; Shanlian Hu MD, MSc, Professor, Fudan University, School of Public Health, Shanghai, China


20


W4: FROM THEORY TO PRACTICE: ExPERIENCES OF SOUTH KOREA HEALTH INSURANCE REVIEW ASSESSMENT AND SERVICE (HIRA) Flamingo (Speakers at this panel were invited, see page 39 for biographical information) Discussion Leaders: Sang Moo Lee MD PhD, Consultant EBH team, Health Insurance Review Assessment and Service, Seoul, South Korea; So-Young Yi PhD, General Manager, Drug Listing Division, Health Insurance Review and Assessment Service, Seoul, South Korea; SeungJin Bae ScD, Senior Researcher, Drug Policy Research Team, Health Insurance Review Assessment and Service, Seoul, South Korea

3:00PM-3:15PM BREAK, EXHIBIT & RESEARCH POSTER PRESENTATION VIEWING Grand Ballroom Refreshments supported by Lionbridge (See page 75 for poster presentations)

3:15PM-4:15PM ISSUE PANELS (See page 52 for Issue Panel descriptions)

HeALTH POLIcY ISSUeSIP1: GAINING ACCESS TO THE ESSENTIAL MEDICINES IN THAILAND THROUGH THE USE OF COMPULSORY LICENSING POLICY: PROS AND CONS (GOOD OR EVIL)? Crane Moderator: Viroj Tangcharoensathien MD, PhD, Director of International Health Policy Program, Bureau of Policy and Strategy, Nonthaburi, Thailand Panelists: Suwit Wibulpolprasert MD, MPH, Senior Advisor on Disease Control, Office of the Permanent Secretary, Ministry of Public Health, Nonthaburi, Thailand;

Sripen Tantivess PhD, Researcher, Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand; TBD, Representative from industry and Pharmaceutical Research and Manufacturer Association (Prema), Bangkok, Thailand

HEALTH CARE REIMBURSEMENT/COVERAGE ISSUES IP2: VARIATIONS IN BIOLOGICS ACCESS IN THE ASIA PACIFIC – IMPLICATIONS FOR REIMBURSEMENT POLICIES Skylark Moderator: Mingliang Zhang PhD, Senior Director, Worldwide Health Economics and Pricing, Johnson & Johnson Pharmaceutical Services, Raritan, NJ, USA Panelists: Karen Eggleston PhD, Fellow, Asia-Pacific Research Center, Stanford University, Stanford, CA, USA; chee Ruey Hsieh PhD, Fellow, Academia SINICA, Taipei, TaiwanIP3: ASEAN HARMONIZATION AND IMPROVING DRUG ACCESS: WHERE ARE THE BENEFITS AND RISKS White Heron (Speakers at this panel were invited, see page 39 for biographical information) Moderator: Anita Kotwani PhD, Associate Professor, Department of Pharmacology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India Panelists: Jesusa Joyce N. Cirunay, Chief, Regulation Division II (GMP Inspectorate), and Head, Vaccine and Biological Products Working Group, Bureau of Food

and Drugs, Muntinlupa City, Philippines; Syed Mohamed Aljunid MD; MSc, PhD, FAMM, Professor of Health Economics & Consultant Public Health Medicine, Senior Research Fellow, United Nations University-International Institute of Global Health (UNU-IIGH), and Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia; Surachat Ngorsuraches, PhD, RPh, Head of Pharmacy Administration Department, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hatyai, Songkla, Thailand

IP4: EARLY ExPERIENCE IN IMPLEMENTING CONDITIONAL COVERAGE DECISIONS WITH EVIDENCE GENERATION IN THE UK AND SOUTH KOREA CONTExT: PRACTICAL AND MeTHODOLOgIcAL cHALLeNgeS Flamingo (Speakers at this panel were invited, see page 39 for biographical information) Moderator: Dae-Seog Heo MD, Professor, Department of Internal Medicine, College of Medicine, Seoul National University, Seoul, South Korea Panelistes: Sang Moo Lee MD, PhD, Consultant EBH Team, Health Insurance Review & Assessment Service, Seoul, South Korea; Kalipso Chalkidou MD, PhD, Associate Director NICE R&D, UK, and Johns Hopkins School of Public Health, USA

USE OF HEALTH ECONOMIC/PHARMACOECONOMIC INFORMATION BY DECISION-MAKERS ISSUESIP5: PHARMACOECONOMICS AND OUTCOME RESEARCH IN INDONESIA, MONGOLIA AND VIETNAM: IS THIS A PRE-REQUISITE FOR THE NEW DRUG REGULATOR? Swan

(Speakers at this panel were invited, see page 39 for biographical information) Moderator: Jawahar S. Bapna PhD, MD, MB, Professor, Pharmaceutical Management, Indian Institute of Health Management Research, Jaipur, India

Panelists: Ahmad fuad Afdhal PhD, Chief Executive Officer, Center for Socio-Economic Studies in Pharmacy, Jakarta, Indonesia; Dungerdorj Densmaa PhD, ScD, Academician of Mongolian Academy of Sciences, Vice President for Academic Affairs, Health Sciences University of Mongolia(HSUM), and President of Mongolian Pharmaceutical Association; Nguyen Thi Bach Yen MD, MSc, Vice Head, Department of Health Economics, Project Coordinator, Vietnam-The Netherland Project in 8 Medical Faculties, and Faculty of Public Health, Hanoi Medical University, Hanoi, Vietnam

4:15PM-4:30PM BREAK, EXHIBIT & RESEARCH POSTER PRESENTATION VIEWING Grand Ballroom Refreshments supported by Lionbridge (See page 75 for poster presentations)

4:30PM-6:00PM SECOND PLENARY SESSION Convention Hall DE deVeloPing eVidenCe USing HealTH TeCHnology aSSeSSmenT (HTa) Simultaneous English/Korean translation provided (See page 39 for biographical information) Activities and achievements of the European Network for Health Technology Assessment (EUnetHTA) and Canadian Agency for Drugs and

Technologies in Health (CADTH) will be presented. Issues on how the existing HTAs can be adapted globally will be discussed. Cases of Asian HTA initiatives in Taiwan and South Korea will be introduced.

Moderator: Isao Kamae MD, DrPH, Professor and Chair, Graduate School of Health Management, Keio University, Tokyo, Japan

Harmonize HTA Globally – Activities and Achievements of EUnetHTA & CADTH Speakers:

Finn Boerlum Kristensen MD, PhD, Director & Professor, Danish Centre for Health Technology Assessment, National Board of Health, Copenhagen, Denmark; Adjunct Professor, University of Southern Denmark; Project Leader, European Network for HTA (EUnetHTA) Jill M. Sanders PhD, President and CEO, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada

HTA Initiatives in Asia – Cases of Taiwan and South Korea Speakers: Tony Yen-Huei Tarn MS, PhD, Senior Researcher, Health Technology Assessment Task Force, Center for Drug Evaluation, Taipei, Taiwan Eui-Kyung Lee PhD, Professor, Graduate School of Clinical Pharmacy, Sookmyung Women’s University, Seoul, South Korea


I. Kamae

F. Kristensen J. Sanders Y. H. Tarn E. Lee

21


6:00PM-7:00PM RESEARCH POSTER AUTHOR DISCUSSION HOUR Grand Ballroom

6:00PM-8:00PM RECEPTION, EXHIBITS & POSTER PRESENTATIONS VIEWING Grand Ballroom (See page 75 for poster presentations)

Reception supported by: TransPerfect Translations

7:00PM-8:00PM EDUCATIONAL SYMPOSIUM (Sponsored by Bristol-Myers Squibb Company) Convention Hall DE Value of antiviral Treatments for Chronic Hepatitis b (See page 57-58 for Symposium descriptions)

(Followed by dinner for symposium attendees)

8:30PM-9:30PM ASIA CONSORTIUM BUSINESS MEETING (By invitation only)

TUESDAY, 9 SEPTEMBER 2008

7:00AM- 8:45AM ISPOR ASIA-PACIFIC MEDICAL DEVICE & DIAGNOSTICS COUNCIL FORUM Flamingo (Continental Breakfast is provided.) With the rapid development of health technology in Asia-Pacific region, health technology assessment and management more and more

plays an important role in the field of medical device & diagnostics to meet multiple health system needs. This forum will provide a platform for the professionals from government, academia and industry in the region to highlight current policies and innovations, discuss issues and challenges, and provide the range of evidence-based tools and resources to help make better health care decisions.

(See page 39 for biographical information) Moderator: Madeleine R. Valera MD, MScIH (Heidelberg), 2008-2010 Vice-Chair, ISPOR Asia-Pacific Medical

Device & Diagnostic Council, and Senior Vice President for Health Finance Policy and Services Sector, Philippine Health Insurance Corporation, Pasig City, Philippines

Health Technology assessment and management Speaker: Jie chen PhD, 2008-2010 Chair, ISPOR Asia-Pacific Medical Device & Diagnostics Council &

Director, Key Lab of Health Technology Assessment, Ministry of Health, and Professor, School of Public Health, Fudan University, Shanghai, China

evidence-based Health Policies for medical devices and diagnostics in asia Speaker: Kai Hong Phua AB, SM, PhD, Professor of Health Policy & Management, Lee Kuan Yew School of Public Policy,

National University of Singapore, Singapore, Singapore innovation in medical Technologies: Value and incentives Speaker: Ashoke Bhattacharjya PhD, Executive Director, Health Economics and Policy, Johnson & Johnson Medical, Asia Pacific, New Delhi, India HTa and accelerated access of new medical Technology to Patients Speaker: Kathy Cargill MSc, MRPharmS, Senior Director, Reimbursement and Health Economics, Medtronic International, Tolochenaz, Switzerland Health Technology assessment in South Korea Speaker: Seong-Hi Park PhD, Director, HTA Team, Health Insurance and Review Assessment & Service, Seoul, South Korea

8:00AM-9:00AM EXHIBIT & RESEARCH POSTER PRESENTATIONS VIEWING Grand Ballroom (See page 75 for poster presentations)

9:00AM-9:15AM WELCOME Convention Hall DE Bong-Min Yang PhD, Program Chair and Professor, School of Public Health, Seoul National University, Seoul, South Korea Chris L. Pashos PhD, 2008-2009 ISPOR President, and Vice President & Executive Director, HERQuLES Health Economic

Research and Quality of Life Evaluation Services Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA

9:15AM-10:45AM THIRD PLENARY SESSION deVeloPing and imPlemenTing PHarmaCoeConomiC gUidelineS Convention Hall DE lessons learned from australia and South Korea (See page 39 for biographical information) This session will give an overview of experience and lessons learned in developing and implementing pharmacoeconomic guidelines in

Australia, the leading country that introduced pharmacoeconomic guidelines to the world. It will also focus on South Korea, where pharmacoeconomic guidelines were issued in 2006, and the guidelines have been officially implemented since 2007. Practical issues in implementing guidelines in South Korea will also be addressed.

Moderator: Bong-Min Yang PhD, Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea Speakers: Rosalie Viney PhD, Associate Professor, and Deputy Director, Centre for Health Economics Research & Evaluation, Sydney, Australia Eun-Young Bae PhD, Assistant Professor, College of Health Sciences, Sanji University, Wonju, South Korea

Schedule of eventS - monday, 8 September / tueSday, 9 September

M. Valera

J. Chen K. Phua A. Bhattacharjya

K. Cargill S. Park

B. Yang C. Pashos

B. Yang

R. Viney E. Bae

22


10:45AM-11:00AM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING Grand Ballroom (See page 75 for poster presentations)

11:00AM-12:00PM RESEARCH PODIUM PRESENTATIONS-SESSION II (Page numbers shown to the left refer to the abstract in this Program & Schedule of Events)

cost-effectiveness Studies White HeronModerator: Wen chen PhD, Professor and Associate Dean, School of Public Health, Fudan University, Shanghai, Chinapg 64 CE1 COST-EFFECTIVENESS ANALYSES OF CHRONIC HEPATITIS B AND C MANAGEMENT IN TAIWAN – BASED ON REAL WORLD DATA FROM THE PILOT HEPATITIS

REIMBURSEMENT PROGRAM Pwu Rf1, Chen CL2, Kao JH2, Lai MY2, 1Taipei Medical University, Taipei, Taiwan, 2National Taiwan University, Taipei, Taiwanpg 64 CE2 A COST-EFFECTIVENESS ANALYSIS FOR CHRONIC HEPATITIS B VIRUS WITH CIRRHOSIS BY DISCRETE EVENT SIMULATION Luh H1, Phua S2, 1National Chengchi University, Taipei, Taiwan, 2Agenix Limited, Singapore, Singapore pg 65 CE3 COST-EFFECTIVENESS OF SMOKING CESSATION IN AUSTRALIA WITH VARENICLINE, A NOVEL PHARMACOTHERAPY Brown A1, Webb K2, Kim H3, Liew D4, 1Pfizer Australia Pty Limited, West Ryde, NSW, Australia, 2Pfizer Inc, Tadworth, Surrey, UK, 3Pfizer Inc, Sydney, NSW, Australia,

4The University of Melbourne, Melbourne, Victoria, Australia pg 65 ce4 THe LONg-TeRM ecONOMIc IMPAcT Of ceRVIcAL cANceR VAccINATION IN TAIWAN You SL1, Tang CH2, Ferko N3, Debicki D3, chen Yc4, Chen CJ1, 1Genomics Research Center, Academia Sinica, Taipei, Taiwan, 2Taipei Medical University, Taipei, Tai-

wan, 3i3 Innovus Research Inc, Burlington, ON, Canada, 4GlaxoSmithKline, Taipei, Taiwan

cost Studies SkylarkModerator: Ahmad fuad Afdhal PhD, Chief Executive Officer, Center for Socio-Economic Studies in Pharmacy, Jakarta, Indonesiapg 65 CS1 COST OF PRODUCTIVITY LOSS DUE TO PREMATURE MORTALITY ATTRIBUTABLE TO ALCOHOL CONSUMPTION IN THAILAND Lertpitakpong c1, Neramitpitagkul P1, Thavorncharoensap M1, Chaikledkaew U2, Teerawattananon Y1, 1Health Intervention and Technology Assessment Program

(HITAP), Nonthaburi, Thailand, 2Faculty of Pharmacy Mahidol University, Ratchathewi, Bangkok, Thailandpg 65 CS2 ANALYSIS OF SOCIOECONOMIC COST OF SMOKING IN KOREA Kim CH1, Song HR2, Park S3, Ko S4, 1Department of Healthcare Policy and Management/Smoking Cessation Clinic of Seoul Paik Hospital, seoul, South Korea, 2Inje

University, Seoul, South Korea, 3Yonsei university, Seoul, South Korea, 4Pfizer Korea, Seoul, South Koreapg 66 cS3 cOST Of SUSPecTeD INVASIVe PNeUMOcOccAL DISeASeS IN VIeTNAMeSe cHILDReN Riewpaiboon A1, Anh DD2, Tho LH3, Kim SA4, Kilgore PE4, 1Faculty of Pharmacy Mahidol University, Ratchathevi, Bangkok, Thailand, 2National Institute of Hygiene

and Epidemiology, Hanoi, Hanoi, Vietnam, 3Khanh Hoa Provincial Public Health Service, Nha Trang, Khanh Hoa, Vietnam, 4International Vaccine Institute, Kwanak, Seoul, South Korea

pg 66 CS4 THE IMPACT OF A HIGHER PD UTILIZATION RATE FOR DIALYSIS TREATMENT ON KOREA’S GOVERNMENT ExPENDITURES chen L1, Bang J2, Walker D3, 1Baxter Healthcare Asia Pacific, Shanghai, China, 2Baxter Healthcare Korea, Seoul, South Korea, 3Baxter Healthcare US, Chicago, IL, USA

Health Policy FlamingoModerator: Syed Mohamed Aljunid MD, MSc, PhD, FAMM, Professor of Health Economics & Consultant, Public Health Medicine, Senior Research Fellow, United Nations University-International Institute of Global Health (UNU-IIGH), HUKM Complex, and Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysiapg 66 HP1 THE IMPLICATIONS OF BENEFIT PACKAGE DESIGN: THE IMPACT ON POOR THAI HOUSEHOLDS OF ExCLUDING RENAL REPLACEMENT THERAPY Prakongsai P1, Tangcharoensathien V2, 1International Health Policy Program (IHPP), Nonthaburi, Nonthaburi, Thailand, 2International Health Policy Program - Thai-

land, Nonthaburi, Thailandpg 66 HP2 SURVeY ON THe cURReNT HUMAN cAPAcITY AND fUTURe NeeDS IN ecONOMIc eVALUATION IN THAILAND chaikledkaew U1, Lertpitakpong C2, Orrawattanakul Y2, Pimsawan N2, Kulpeng W2, Thavorncharoensap M2, Teerawattananon Y2, Tangcharoensathien V3, 1Faculty of

Pharmacy Mahidol University, Ratchathewi, Bangkok, Thailand, 2Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand, 3Interna-tional Health Policy Program - Thailand, Nonthaburi, Thailand

pg 67 HP3 TREATMENT PATTERN AND OUTCOME ASSESSMENT OF ASTHMATIC PATIENTS ADMITTED TO ACCIDENT & EMERGENCY DEPARTMENT (ED) IN A TERTIARY TeAcHINg HOSPITAL

Hussain SH1, Wong SW1, Ramli MN2, Raja Mohamed AA2, 1University of Malaya, Kuala Lumpur, Federal Territor, Malaysia, 2University Malaya Medical Centre, Kuala Lumpur, Federal Territor, Malaysia

pg 67 HP4 A STUDY OF MEDICINE PRICES, AVAILABILITY AND AFFORDABILITY IN SHANGHAI, CHINA Ye L1, Hu S2, 1School of Public Health, Fudan University, Shanghai, China, 2Fudan University, Shanghai, China

Research on Methods SwanModerator: Madeleine R. Valera MD, MScIH (Heidelberg), Senior Vice President for Health Finance Policy and Services Sector, Philippine Health Insurance Corporation, CityState Center, Pasig City, Philippinespg 67 ME1 A NEW APPROACH FOR MONITORING DRUG PRICE BEHAVIORS: MISCELLANEOUS ACQUISITION CAPABILITY (MAC) Udom-aksorn S1, Sakulbumrungsil R2, 1Prince of Songkla University, Hatyai, Songkhla, Thailand, 2Chulalongkorn University, Patumwan, Bangkok, Thailand pg 67 ME2 THE QUANTITY COST-EFFECTIVENESS ACCEPTABILITY CURVE BASED ON THE FULL INFORMATION OF INDIVIDUAL NET BENEFIT IN HEALTH-RELATED

ecONOMIc eVALUATION Kim S, Suh J, Kim KH, Kim JS, Kim HK, Novartis, Seoul, South Koreapg 68 ME3 VALIDATING A SURVEY INSTRUMENT USING NONPARAMETRIC ITEM RESPONSE THEORY – APPLICATION OF KERNEL REGRESSION Lin HW1, Pickard AS2, Karabatsos G3, Mahady GB2, Crawford SY2, Popovich NG2, 1China Medical University, Taichung, Taiwan, 2College of Pharmacy, University of

Illinois at Chicago, Chicago, IL, USA, 3College of Education, University of Illinois at Chicago, Chicago, IL, USApg 68 ME4 FACTORS AFFECTING WILLINGNESS-TO-PAY FOR TREATMENT OF BLINDNESS IN THAI POPULATION Kulpeng W, Natanant S, Thavorncharoensap M, Teerawattananon Y, Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand

Schedule of eventS - tueSday, 9 September

23


Patient-Reported Outcomes Studies CraneModerator: Sang-Cheol Bae MD, PhD, MPH, Professor and Director, The Hospital for Rheumatic Diseases, and Head, Section for Clinical Epidemiology and Economics, Han-yang University, Seoul, South Koreapg 68 PR1 HEALTH-RELATED UTILITY OF AUSTRALIAN RHEUMATOID ARTHRITIS PATIENTS CORRELATES WITH HAQ BUT NOT TOTAL TENDER AND SWOLLEN JOINT COUNTS Norris S1, Harvey C1, Elliott L1, Standfield L1, Riordan J2, Hall S3, Day R4, Nash P5, Thiru K6, Robertson J6, Palmer T6, 1Health Technology Analysts Pty Ltd, Sydney,

Australia, 2Illawara Rheumatology, Woollongong, Australia, 3Cabrini Medical Centre, Malvern, Australia, 4St Vincents Clinical Trial Centre, Sydney, Australia, 5Sixth Avenue Specialist Centre, Cotton Tree, Australia, 6Wyeth Australia, Sydney, Australia

pg 68 PR2 HEALTH-RELATED QUALITY OF LIFE AND ITS ASSOCIATED FACTORS IN PATIENTS WITH TYPE 2 DIABETES IN SOUTH KOREA Jo MW1, Lee WJ2, Noh JH3, Song KH4, Choi YJ5, 1Dongguk University, Gyeongju, Gyeongbuk, South Korea, 2Inje University Sanggye Paik Hospital, Seoul, South Korea,

3Inje University Ilsan Paik Hospital, Ilsan, Gyeonggi-Do, South Korea, 4Kunkuk University Hospital, Seoul, South Korea, 5Sanofi-Aventis Korea, Seoul, South Koreapg 69 PR3 DOES COMBINING AMLODIPINE AND ATORVASTATIN INTO A SINGLE PILL IMPROVE ADHERENCE IN THE TARGET POPULATION? COMBINED EVIDENCE FROM

TWO US RETROSPECTIVE DATABASE STUDIES Earle KL, Delahoy PJ, Dabin B, Brown AJ, Pfizer Australia Pty Ltd, West Ryde, NSW, Australia pg 69 PR4 DETERMINATION OF THE LONGITUDINAL VALIDITY AND MINIMALLY IMPORTANT DIFFERENCE OF THE 8-ITEM PARKINSON’S DISEASE QUESTIONNAIRE (PDQ-8) Zhao YJ1, Tan LC2, Lau PN2, Au WL2, Li SC3, Luo N4, 1National University of Singapore, Singapore, Singapore, Singapore, 2National Neuroscience Institute, Singapore,

Singapore, 3University of Newcastle, Callaghan, NSW, Australia, 4National University of Singapore, Singapore, Singapore

12:00PM-1:30PM LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING Grand Ballroom (See page 75 for poster presentations) Lunch supported by Korea Tourism Organization

12:30PM-1:30PM EDUCATIONAL SYMPOSIUM (Sponsored by IMS Health) Convention Hall DE evolving Trends in HTa: Comparing the evidence (See page 57-58 for Symposium descriptions)

1:30PM-2:30PM WORKSHOPS-SESSION II (See page 53 for Workshop descriptions)

ecONOMIc OUTcOMeS ReSeARcHW6: eXPeRT OPINION AND cOUNTRY SPecIfIc MODeL ADAPTATIONS Skylark Discussion Leaders: Bruce Crawford MA, MPH, General Manager, Asia, Mapi Values, Tokyo, Meguro, Japan; Chris Evans PhD, MPH, Director of Economics and Out-

comes, Mapi Values, Boston, MA, USA

HeALTH cARe POLIcY DeVeLOPMeNT USINg OUTcOMeS ReSeARcHW7: PHARMAcOecONOMIc gUIDeLINeS IN cHINA AND THAILAND Flamingo (Speakers at this workshop were invited, see page 39 for biographical information) application of Pharmacoeconomics & outcomes research in China Discussion Leader: Ming Tang PhD, Principal Director, Center of Pharmacoeconomic Evaluation, Chinese Medical Doctor Association, Beijing, China The development and Potential applications of Pharmacoeconomic guidelines in Thailand Discussion Leader: Yot Teerawattananon PhD, Health Intervention and Technology Assessment Program, Ministry of Public Health, ThailandW8: HeALTH TecHNOLOgY ASSeSSMeNT IN ASIAN-PAcIfIc cOUNTRIeS White Heron Discussion Leaders: candace gunnarsson edD, President CEO, S2 Statistical Solutions, Inc, Cincinnati, OH, USA; Susan Ross MD, Consultant, SDRoss Consulting, Cohas-

set, MA, USA; Harry J. Kotlarz MBA, BS, Director, Health Economics and Reimbursement, DePuy Orthopaedics Inc, Warsaw, IN, USA

PATIeNT-RePORTeD OUTcOMeS ReSeARcHW9: THE ROLE OF UTILITIES IN SUPPORTING MARKET ACCESS IN ASIA: LESSONS LEARNT FROM NICE & CDR Swan Discussion Leaders: Andrew Lloyd BSc, DrPH, Director, Oxford Outcomes, Oxford, UK; Nan Luo PhD, Research Fellow, National University of Singapore, Centre for Health

Services Research, Singapore, Singapore; Paul Quarterman MSc, Director, Oxford Outcomes, Oxford, UK

USe Of ReAL WORLD DATAW10: THe USe Of ReAL WORLD DATA TO ASSeSS cOMPLIANce AND ecONOMIcS IN HYPeRTeNSION Crane Discussion Leaders: Diana Brixner RPh, PhD, Associate Professor, University of Utah College of Pharmacy, Department of Pharmacotherapy, Salt Lake City, UT, USA;

Joseph Biskupiak PhD, MBA, Research Associate Professor, University of Utah, College of Pharmacy, Department of Pharmacotherapy, Salt Lake City, UT, USA; gary M Oderda PharmD, MPH, Professor, University of Utah, Department of Pharmacotherapy, Salt Lake City, UT, USA; Abdulkadir Keskinaslan MD, MBA, MPH, HE Manager, Novartis Pharma AG, Global HE & OR CVM, Basel, Switzerland

2:30PM-2:45PM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING Grand Ballroom (See page 75 for poster presentations)

2:45PM-3:45PM RESEARCH PODIUM PRESENTATIONS-SESSION III (Page numbers shown to the left refer to the abstract in this Program & Schedule of Events)

cancer FlamingoModerator: Tini Q. Chau Nguyen PharmD, HE Dipl., Director, Health Outcomes & Market Access, Asia Pacific, Sanofi-Aventis, Paris, Francepg 69 CN1 THE IMPACT OF SUSPECTED SUPERFICIAL BLADDER CANCER ON HEALTH CARE RESOURCE UTILIZATION: A KOREAN PERSPECTIVE Barwell AC1, Zyczynski T2, Hong SJ3, 1Abacus International, Bicester, Oxon, UK, 2GE Healthcare, Princeton, NJ, USA, 3Severance Hospital, Seoul, South Korea pg 68 CN2 COST-MINIMIZATION ANALYSIS OF CAPECITABINE FOR ADVANCED GASTRIC CANCER IN TAIWAN chao Y1, Chang CS2, Chen JS3, Chen LT4, Chung CH5, Hsieh RK6, Hwang WS7, Yang L8, De Reyder F9, 1Taipei Veterans General Hospital, Taipei, Taiwan, 2Changhua

Christian Memorial Hospital, Changhua, Taiwan, 3Chang Gung Memorial Hospital, LinKou, Taiwan, 4National Health Research Institutes, Taipei, Taiwan, 5Kaoshiung Medical University Hospital, Kaoshiung, Taiwan, 6Mackay Memorial Hospital, Taipei, Taiwan, 7Chi Mei Medical Center, Tainan, Taiwan, 8Roche Products Ltd, Taipei, Taiwan, 9F. Hoffmann-La Roche AG, Basel, Switzerland


24


pg 70 cN3 cOST-effecTIVeNeSS Of cHeMOTHeRAPY IN NON-SMALL ceLL LUNg cANceR Lim S1, Lim G1, Goh A2, 1Kuala Lumpur Hospital, Kuala Lumpur, Malaysia, 2ClinResearch Sdn Bhd, Kuala Lumpur, Malaysiapg 70 CN4 IMATINIB IS COST-EFFECTIVE THAN INTERFERON-ALPHA (IFN) FOR PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA FROM

THE CHINESE PUBLIC HEALTH CARE SYSTEM PERSPECTIVE Wang C1, chen Z2, Feng W3, 1Shanghai Jiaotong University Affiliated First Hospital, Shanghai, Shanghai, China, 2Shanghai Fudan University Affiliated Huashan

Hospital, Shanghai, China, 3Novartis Pharmaceuticals, Florhem Park, NJ, USA

cardiovascular Disease SkylarkModerator: xin (Sam) Ye MS, PhD, Associate Director, i3 Innovus, An Ingenix Company, Eden Prairie, MN, USApg 70 CV1 TO COMPARE THE THERMAL RESPONSE OF NIFEDIPINE WITH GINKGO IN PATIENTS WITH RAYNAUD’S DISEASE BY DIGITAL INFRARED THERMOGRAPHIC

IMAGING; KOREAN RAYNAUD DITI STUDY Choi WS1, Kim SH1, Ju SY1, Chung JH1, Lee JB2, Lee DH3, Kim CM1, 1Catholic University, Seoul, South Korea, 2Korea University, Ansan, South Korea, 3Ewha womans’

University hospital, Seoul, South Koreapg 70 CV2 A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY OF STATINS ON REDUCING ACUTE CORONARY SYNDROME AND STROKE EVENTS Tamteeranon Y1, Chaikledkaew U1, Khonputsa P2, Teerawattananon Y1, 1Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand,

2Setting Priority using Information on Cost-Effectiveness (SPICE), Nonthaburi, Thailandpg 71 CV3 UTILIZATION OF NEW DRUG AND MEDICAL ExPENDITURE OF HYPERTENSION PATIENTS: EMPIRICAL EVIDENCE FROM ANGIOTENSIN II RECEPTOR BLOCKERS

IN TAIWAN Liu YM1, Kao Yang YH2, Chang CY2, 1National Cheng Kung University, Tainan, Taiwan, 2National Cheng Kung University, Tainan, Taiwan pg 71 CV4 THE CLINICAL AND ECONOMIC BENEFIT OF CHANGING THE NATIONAL REIMBURSEMENT CRITERIA FOR CHOLESTEROL LOWERING DRUG THERAPY IN KOREA Kang HY1, Liew D2, Ko S3, Kim J4, 1Yonsei University, Seoul, South Korea, 2The University of Melbourne, Melbourne, Victoria, Australia, 3Pfizer Korea, Seoul, South

Korea, 4Konyang University, Chungnam, South Korea

Diabetes White HeronModerator: Kenneth KC Lee JP, BSc(Pharm), MPhil, PhD, Professor & Associate Director (External Affairs), School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Chinapg 71 DB1 RISK FACTORS FOR AND INCIDENCE RATE OF TYPE 2 DIABETES RELATED HOSPITALIZATION USING CLAIMS DATA IN SOUTH KOREA Kim CM1, Choi IS2, Jang SM3, Gerth W4, Suh DC2, Choi WS1, 1Catholic University, Seoul, Suhcho-gu, South Korea, 2Rutgers University, Piscataway, NJ, USA, 3Health

Insurance Review Agency, Seoul, South Korea, 4Merck & Co., Inc, Whitehouse Station, NJ, USA pg 71 DB2 A SURVEY OF DIABETES KNOWLEDGE AMONG THE GENERAL POPULATION IN THAILAND Pongmesa T1, Wee HL1, Li SC2, 1National University of Singapore, Singapore, Singapore, 2University of Newcastle, Callaghan, NSW, Australia pg 72 DB3 ACARBOSE IN ADDITION TO ExISTING TREATMENTS IN PATIENTS WITH TYPE 2 DIABETES: HEALTH ECONOMIC ANALYSES IN A CHINESE SETTING chen X1, Clegg JP2, Chen L1, Yu H3, Wittrup-Jensen KU4, Valentine WJ2, 1Fu Dan University, Shanghai, China, 2IMS Health, Basel, Switzerland, 3Bayer Healthcare Co.

Ltd, Shanghai, China, 4Bayer Schering Pharma AG, Berlin, Germany pg 72 DB4 MODELLING THE COST-EFFECTIVENESS OF ACARBOSE IN PREVENTING TYPE 2 DIABETES IN A SOUTH KOREAN SETTING JongMann K1, Clegg JP2, Chang K1, JuYeol P1, Wittrup-Jensen KU3, Palmer AJ4, Roze S4, Valentine WJ5, 1Bayer, Seoul, South Korea, 2IMS, Allschwil, Switzerland,

3Bayer Schering Pharma AG, Berlin, Germany, 4CORE - Center for Outcomes Research, A Unit of IMS, Allschwil, Basel, Switzerland, 5IMS Health, Basel, Switzerland

Infection SwanModerator: Jens grueger PhD, Novartis Pharma AG, Global Marketing & Sales, Head Global Pricing & Reimbursement, Basel, Switzerlandpg 72 IF1 EFFECTIVENESS AND SAFETY OF COMBINATION THERAPY OF ZIDOVUDINE AND LAMIVUDINE FOR PREVENTING THE RISK OF MOTHER-TO-CHILD TRANSMIS-

SION Of HIV: A SYSTeMATIc ReVIeW Wang L1, Li Y2, Sun X2, Peng L1, 1Sichuan University, Chengdu, Sichuan, China, 2West China Hospital, Sichuan University, Chengdu, Chinapg 72 IF2 AN ECONOMIC EVALUATION OF ANIDULAFUNGIN IN THE TREATMENT OF INVASIVE CANDIDIASIS IN KOREA Jo c1, Kim SI2, Jun S3, 1Hallym University, Chuncheon, South Korea, 2Catholic University, Seoul, South Korea, 3Korea Institute of Environment and Health, Seoul,

South Korea pg 73 If3 THe QUALITY Of SYSTeMATIc ReVIeWS OR MeTA-ANALYSeS ON PeRINATAL ANTIReTROVIRAL THeRAPIeS fOR PReVeNTINg MOTHeR-TO-cHILD TRANSMIS-

SION Of HIV Wang L1, Peng L1, Sun X2, Li Y2, 1Sichuan University, Chengdu, Sichuan, China, 2West China Hospital, Sichuan University, Chengdu, China pg 73 IF4 A HEALTH ECONOMICS MODEL TO ESTIMATE THE COST DIFFERENCE BETWEEN STOCKPILING VERSUS NOT STOCKPILING PRE-PANDEMIC INFLUENZA VACCINE Tucker D1, Williams P2, 1GlaxoSmithKline Biologicals, Wavre, Belgium, 2Navitas BioPharma Consulting, Buckinghamshire, UK

Mental Health CraneModerator: Guk-Hee Suh MD, PhD, Professor of Psychiatry, Hallym University Medical Center, Hangang Sacred Heart Hospital, Seoul, Koreapg 73 MH1 PATIeNT AND PHYSIcIAN SATISfAcTION WITH RISPeRIDONe LONg-AcTINg INJecTION: INTeRIM ReSULTS fROM THe eLecTRONIc ScHIZOPHReNIA TReAT-

MENT ADHERENCE REGISTRY (E-STAR) IN KOREA Lee MS1, Kim YS2, Lee DG3, Paik IH4, Lee HK4, Jung IK1, Lee JG5, Hah TM6, Zhao Z7, 1Korea University, Seoul, South Korea, 2Seoul National University, Seoul, South Ko-

rea, 3Goyang Mental Hospital, Goyang, South Korea, 4The Catholic University of Korea, Seoul, South Korea, 5Masan Dongsuh Hospital, Masan, South Korea, 6Busan Dongrae Hospital, Busan, South Korea, 7JJPS, Raritan, NJ, USA

pg 73 MH2 HOSPITALIZATION ASSOcIATeD WITH RISPeRIDONe LONg AcTINg INJecTION TReATMeNT IN ScHIZOPHReNIA: 6-MONTH ReSULTS fROM THe eLecTRONIc SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN KOREA

Kim YS1, Lee MS2, Lee DG3, Paik IH4, Lee HK4, Jung IK2, Lee JG5, Hah TM6, Zhao Z7, 1Seoul National University, Seoul, South Korea, 2Korea University, Seoul, South Korea, 3Goyang Mental Hospital, Goyang, South Korea, 4The Catholic University of Korea, Seoul, South Korea, 5Masan Dongsuh Hospital, Masan, South Korea, 6Busan Dongrae Hospital, Busan, South Korea, 7JJPS, Raritan, NJ, USA


25


pg 74 MH3 ecONOMIc eVALUATION Of PALIPeRIDONe eR IN THe TReATMeNT Of ScHIZOPHReNIA PATIeNTS IN TAIWAN Yang YK1, Liu CY2, Pwu RF3, Ko SY4, Tsai Ic4, 1National Cheng Kung University, Tainan, Taiwan, 2Chang Gung Memorial Hospital, Tao Yuan, Taiwan, 3Taipei Medical

University, Taipei, Taiwan, 4Janssen Cilag Taiwan, Taipei, Taiwanpg 74 MH4 RISPeRIDONe LONg AcTINg INJecTION TReATMeNT IN ScHIZOPHReNIA: 6-MONTH ReSULTS fROM THe eLecTRONIc ScHIZOPHReNIA TReATMeNT

ADHERENCE REGISTRY (E-STAR) IN KOREA Lee MS1, Kim YS2, Lee DG3, Paik IH4, Lee HK4, Jung IK1, Lee JG5, Hah TM6, Zhao Z7, 1Korea University, Seoul, South Korea, 2Seoul National University, Seoul, South

Korea, 3Goyang Mental Hospital, Goyang, South Korea, 4The Catholic University of Korea, Seoul, South Korea, 5Masan Dongsuh Hospital, Masan, South Korea, 6Busan Dongrae Hospital, Busan, South Korea, 7JJPS, Raritan, NJ, USA


4:00PM-5:00PM WORKSHOPS - SESSION III (See page 53 for Workshop descriptions)

cLINIcAL OUTcOMeS ReSeARcHW11: WEB-BASED SYSTEMATIC REVIEWS – A NEW TOOL FOR AN EVOLVING PROCESS White Heron Discussion Leader: Peter O’Blenis BCS, MBA, Vice-President, Product Development, TrialStat Corporation, Ottawa, ON, Canada

ecONOMIc OUTcOMeS ReSeARcH W12: IS ONE-PART MODEL ENOUGH FOR ANALYZING HEALTH CARE COST DATA? Skylark Discussion Leaders: xin (Sam) Ye MS, PhD, Associate Director, i3 Innovus, An Ingenix Company, Eden Prairie, MN, USA; Henry Joe Henk PhD, Director, i3 Innovus, An

Ingenix Company, Eden Prairie, MN, USA

PATIeNT-RePORTeD OUTcOMeS ReSeARcHW14: WILLINgNeSS TO PAY fOR A QALY IN eAST ASIA Swan Discussion Leaders: Kiichiro Tsutani MD, PhD, Professor, The University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan; Takashi fukuda PhD,

Associate Professor, The University of Tokyo, School of Public Health, Tokyo, Japan; Sang-Cheol Bae MD, PhD, MPH, Professor, Hanyang University College of Medicine, Seoul, South Korea; Hui-chu Lang PhD, Associate Professor, National Yang-Ming University, Institute of Hospital and Health Care Administration, Taipei, Taiwan

USe Of ReAL WORLD DATAW15: PAYING FOR PILLS BY RESULTS: PERFORMANCE-BASED REWARDS FOR INNOVATION AND THEIR IMPLICATIONS FOR THE ASIA-PACIFIC REGION Flamingo Discussion Leaders: Lou garrison PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Department of Pharmacy, Seattle,

WA, USA; Sean D. Sullivan PhD, Professor, University of Washington, Department of Pharmacy, Seattle, WA, USA; Adrian Towse MPhil, Director, Office of Health Eco-nomics, London, UK


5:15PM-6:00PM ISPOR RESEARCH PRESENTATION AWARDS Convention Hall DE Bong-Min Yang PhD, Program Chair and Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea

ISPOR 4th ASIA-PACIFIC CONFERENCE ANNOUNCEMENT Convention Hall DE Surachat Ngorsuraches PhD, RPh, Program Co-Chair, ISPOR 4th Asia-Pacific Conference, and Head of Pharmacy Administration Department, Faculty of Phar-

maceutical Sciences, Prince of Songkla University, Songkla, Thailand Vithaya Kulsomboon PhD, Program Co-Chair, ISPOR 4th Asia-Pacific Conference, President, ISPOR Thailand Chapter, Associate Professor & Chair of Social

Pharmacy Department, and Director of Graduate Program in Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand

CLOSING REMARKS Convention Hall DE Bong-Min Yang PhD, Program Chair and Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea


26


CANCER (PCN)CARDIOVASCULAR DISORDERS (PCV)DIABETES/ENDOCRINE DISORDERS (PDB)GI DISORDERS (PGI)HEALTH POLICY (PHP)

INDIVIDUAL’S HEALTH (PIH)INFECTION (PIN)CONCEPTUAL PAPERS & RESEARCH ON METHODS (PMC)MENTAL HEALTH (PMH)MUSCULAR-SKELETAL DISORDERS (PMS)

NEUROLOGICAL DISORDERS (PND)RESPIRATORY-RELATED DISORDERS (PRS)SENSORY SYSTEMS DISORDERS (PSS)SYSTEMIC DISORDERS/CONDITIONS (PSY)URINARY/KIDNEY DISORDERS (PUK)

Research Poster Presentations

cANceR - clinical Outcomes Studiespg 75 PCN1 CELL PERMEABLE P27 (CP-P27) INDUCES APOPTOSIS IN CANCER CELLS Park KM, Jo D, ProCell Therapeutics Inc, Gwangju, South Koreapg 75 PcN2 DEVELOPMENT OF CELL PERMEABLE P18 AS A PROTEIN-BASED ANTI-CELL CYCLE PROGRESSION AGENT Kim S1, Park K2, Lim J2, Jo D1, 1Chonnam National University, Gwangju, Jeonnam, South Korea, 2ProCell Therapeutics Inc, Gwangju, Jeonnam, South Korea

cANceR - cost Studiespg 75 PCN3 ESTIMATING THE CLINICAL AND ECONOMIC IMPACT OF PROPHYLACTIC CERVICAL CANCER VACCINATION IN JAPAN USING A MARKOV MODEL Arakawa I1, Van Kriekinge G2, Demarteau N2, Fukuda T3, 1GlaxoSmithKline K.K, Tokyo, Tokyo, Japan, 2GlaxoSmithKline Biologicals, Wavre, Belgium, 3The Univer-

sity of Tokyo, Tokyo, Japanpg 75 PCN4 ECONOMIC EVALUATION OF SORAFENIB VS. BEST SUPPORTIVE CARE IN HEPATOCELLAR CARCINOMA IN SOUTH KOREA Jung S1, Hutchins V2, Muszbek N3, Chang M1, Shah S4, 1Bayer Korea, Seoul, South Korea, 2United BioSource Corporation, Bethesda, MD, USA, 3United BioSource

Corporation, London, UK, 4Bayer HealthCare Pharmaceuticals, West Haven, CT, USApg 75 PcN5 ecONOMIc eVALUATION Of ceRVIcAL cANceR PReVeNTIONS AND cONTROL PROgRAMS IN THAILAND Praditsitthikorn N1, Riewpaiboon A2, Teerawattananon Y1, 1Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand, 2Faculty of

Pharmacy Mahidol University, Ratchathewi, Bangkok, Thailand pg 76 PcN6 COST-OF-ILLNESS ANALYSIS OF HEPATOCELLULAR CARCINOMA (HCC) IN SLOVAKIA BASED ON CALCULATION OF COSTS FROM HEALTH INSURANCE DATABASE Bielik J1, Lukac M2, Zatko D3, Foltán V4, 1Trencin University, Trencín, Slovak Republic, 2Bayer Schering Pharma, Bratislava, Slovak Republic, 3General Health

Insurance, Bratislava, Slovak Republic, 4Comenius University, Bratislava, Slovak Republicpg 76 PcN7 PATIENTS’ WILLINGNESS TO PAY FOR A NEW DRUG TREATMENT OF LUNG CANCER Lang Hc, Lan CF, National Yang-Ming University, Taipei, Taiwanpg 76 PcN8 THe LIfeTIMe TReATMeNT cOST Of INVASIVe ceRVIcAL cANceR IN THAILAND Praditsitthikorn N1, Riewpaiboon A2, Chichareon S3, Teerawattananon Y1, 1Health Intervention and Technology Assessment Program (HITAP), Nonthaburi,

Thailand, 2Faculty of Pharmacy Mahidol University, Ratchathewi, Bangkok, Thailand, 3Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand

pg 76 PcN9 COST-EFFECTIVENESS ANALYSIS OF NILOTINIB COMPARED WITH DASATINIB AND HIGH DOSE IMATINIB ON THE TREATMENT OF CHRONIC MYELOID LEUKEMIA Park SY1, Song HJ1, Lee JH2, Heo JH2, Lee EK1, 1Sook Myung Women’s University, Seoul, South Korea, 2Graduate School of Pharmacy, SookMyung Women’s

University, Seoul, South Koreapg 77 PcN10 THERAPEUTIC PATTERNS OF CARE FOR ADVANCED BREAST CANCER PATIENTS AFTER FAILURE OF AN ANTHRACYCLINE AND A TAxANE IN KOREA choi Se, Kim S, Seoul National University, Seoul, South Korea

cANceR - Patient-Reported Outcomes Studiespg 77 PcN11 THe IMPAcT Of THe PROJecT Of eNHANcINg cOVeRAge RATe fOR PATIeNTS WITH cANceR Lee SM, Nam MH, Yoon SH, Kim BY, Choi MR, Cho HS, Lee KD, Health Insurance Review & Assessment Services, Seoul, South Koreapg 77 PcN12 MeASURINg UTILITY WeIgHTS fOR SeVeRe STOMAcH cANceR Kim HJ1, Rhee J2, Lee EK1, 1Sook Myung Women’s University, Seoul, South Korea, 2Sungkyunkwan University, Suwon, Gyeonggi-do, South Koreapg 77 PcN13 VALUATION OF THE ECONOMIC BENEFITS OF HUMAN PAPILLOMAVIRUS VACCINE IN TAIWAN Liao cH, Tang CH, Pwu RF, Chow I, Huang SY, Taipei Medical University, Taipei, Taiwan

CANCER - Health Care Use & Policy Studiespg 77 PcN14 ASSESSING THE APPROPRIATNESS AND FEASIBILITY OF USING PET-CT SCAN IN THAILAND Yamabhai I, Praditsitthikorn N, Teerawattananon Y, Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailandpg 78 PcN15 BASIC ATTITUDE OF PHYSICIANS INVOLVED IN BREAST CANCER TREATMENT TOWARDS USE OF GENERIC ANTI-CANCERDRUGS IN JAPAN Saito S1, Shimozuma K2, Fukuda T3, Ohashi Y4, Fukui N5, Mouri M5, 1Kochi Women’s University, Kochi, Japan, 2University of Marketing and Distribution Sciences

/ Public Health Research Foundation, Kobe, Hyogo, Japan, 3Tokyo University, Tokyo, Japan, 4University of Tokyo, Bunkyo-ku, Tokyo, Japan, 5Japan Clinical Re-search Support Unit, Bunkyo-ku, Tokyo, Japan

pg 78 PcN16 PATTeRN Of OPIOID USe AND ITS ASSOcIATION WITH HeALTH cARe SYSTeM AMONg OecD cOUNTRIeS: OXYcODONe-TO-MORPHINe RATIO Kim YA, Shin DW, Yun YH, National Cancer Center, Goyang-si, Gyeonggi-do, South Korea

research poster presentationsmonday, 8 September: 8:00am-8:00pm & tueSday, 9 September: 8:00am-6:00pm

poSter author dIScuSSIon hour: monday, 8 September: 6:00pm-7:00pm

27

Page numbers shown to the left refer to the abstract in this Program & Schedule of Events






pg 78 PcN17 CONSIDERATIONS ASSOCIATED WITH THE USE OF INTERIM DATA FOR REIMBURSEMENT SUBMISSIONS Delahoy PJ, Pfizer Australia, West Ryde, NSW, Australia

cARDIOVAScULAR DISORDeRS - clinical Outcomes Studiespg 78 PcV1 RACIAL/ETHNIC DIFFERENCES IN THE PREVALENCE OF METABOLIC SYNDROME AND IMPACT OF RACE/ETHNICITY ON OUTCOMES AMONG THOSE WITH

METABOLIC SYNDROME Stankus AP, Saluja P, Consumer Health Sciences International, Princeton, NJ, USApg 79 PcV2 THE HEALTH OUTCOME AND BENEFITS OF CONTINUOUS BLOOD GAS MONITORING ADAPTATION Oláh A1, Varga G1, Müller Á1, Betlehem J1, Kriszbacher I1, Boncz I1, Sebestyén A2, Vas g1, Józsa R1, Bódis J1, 1University of Pécs, Pécs, Hungary, 2National Health

Insurance Fund Administration, Budapest, Hungary pg 79 PcV3 CLINICAL OUTCOME AND COST EVALUATION OF THERAPEUTIC INTERCHANGE PROGRAM OF ANGIOTENSIN-RECEPTOER BLOCKERS IN HYPERTENSIVE

PATIeNTS Lin YY, Sun KL, Chien SC, Taipei Medical University Hospital, Taipei, Taiwanpg 79 PcV4 IS STRESS THE TRIGGER OF A HEART ATTACK? Kriszbacher I, Bódis J, Betlehem J, Koppán Á, Kőhalmi A, Vas g, Vas B, Boncz I, University of Pécs, Pécs, Hungary pg 79 PcV5 A STUDY OF THE ASSOCIATION BETWEEN COMBINED USE OF VARIOUS DIURETICS WITH DIGOxIN AND THE RISK OF HOSPITALIZATION FOR DIGOxIN

INTOXIcATION AMONg PATIeNTS WITH cHRONIc HeART fAILURe IN TAIWAN Su cY, Wang MT, School of Pharmacy, National Defense Medical Center, Taipei, Taiwanpg 79 PcV6 IS THE ExPOSURE TO DIGOxIN-CLARITHROMYCIN INTERACTION ASSOCIATED WITH AN INCREASED RISK OF HOSPITALIZATION FOR DIGOxIN TOxICITY

AMONG PATIENTS WITH CHRONIC HEART FAILURE? Wang MT1, Su CY1, Chan ALF2, 1School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, 2Department of Pharmacy, Chi Mei Medical Center, Tainan,

Taiwanpg 80 PcV7 ACUTE STROKE MANAGEMENT AND PATIENT SAFETY IN HUNGARY Betlehem J1, Veres R2, Kriszbacher I1, Olah A3, Sebestyen A4, Marton-Simora J5, Nagy G5, Vas g1, Bódis J1, Boncz I1, 1University of Pécs, Pécs, Hungary, 2BAZ

County Hospital, Miskolc, Hungary, 3University of Pecs, Pecs, Hungary, 4National Health Insurance Fund Administration, Pecs, Hungary, 5University of Pécs Faculty of Health Sciences, Pécs, Hungary

cARDIOVAScULAR DISORDeRS - cost Studiespg 80 PcV8 COST-EFFECTIVENESS ANALYSIS OF ANTIPLATELET THERAPY IN THE PREVENTION OF RECURRENT STROKE IN TAIWAN chang YT, Chien SC, Taipei Medical University, Taipei, Taiwan pg 80 PcV9 COST-EFFECTIVENESS OF EZETIMIBE-SIMVASTATIN FIxED-DOSE COMBINATION VS ATORVASTATIN THERAPY IN KOREA Kim CM1, Kim M2, Cho E2, Gerth W3, Davies GM4, 1Catholic University, Seoul, Suhcho-gu, South Korea, 2MSD Korea, Seoul, South Korea, 3Merck & Co., Inc, White-

house Station, NJ, USA, 4Merck and Co, Blue Bell, PA, USApg 80 PcV10 ASSeSSINg cOST-effecTIVeNeSS Of STATINS fOR THe PRIMARY PReVeNTION Of cARDIOVAScULAR DISeASe IN THAILAND Khonputsa P1, Tamteeranon Y2, Veerman L3, Vos T3, Lim S4, Chaikledkaew U5, Teerawattananon Y2, 1Setting Priority using Information on Cost-Effectiveness

(SPICE) Project, Nonthaburi, Thailand, 2Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand, 3University of Queensland, Brisbane, Australia, 4University of Washington, Seattle, WA, USA, 5Faculty of Pharmacy Mahidol University, Ratchathewi, Bangkok, Thailand

pg 81 PcV11 cOST-effecTIVeNeSS eVALUATION Of DIffeReNT STATIN TReATMeNT STRATegIeS fROM THe THAI HeALTH SYSTeM PeRSPecTIVe Anukoolsawat P1, Komolsai T2, Gandhi S3, Costa-Scharplatz M4, 1Praram 9 Hospital, Bangkok, Thailand, 2AstraZeneca, Bangkok, Thailand, 3AstraZeneca, Wilm-

ington, DE, USA, 4AstraZeneca, Södertälje, Sweden pg 81 PcV12 COST-EFFECTIVENESS OF CLINICAL PHARMACY SERVICES ON HYPERLIPIDAEMIC MANAGEMENT IN A PUBLIC HOSPITAL OF HONG KONG Lee VWY, Chung JS, Lee KK, Tomlinson B, The Chinese University of Hong Kong, Hong Kong, Chinapg 81 PcV13 AN ECONOMIC EVALUATION OF CLOPIDOGREL IN SECONDARY PREVENTION OF ISCHEMIC EVENTS IN HIGH-RISK POPULATIONS – A TAIWANESE ANALYSIS Li AH1, Annemans L2, 1Far Eastern Memorial Hospital, Pan-Chiao, Taipei, Taiwan, 2Ghent University, Gent, Belgiumpg 81 PcV14 COST-EFFECTIVENESS ANALYSIS OF STROKE REHABILITATION STRATEGIES IN EASTERN CHINA O’Prinsen AC1, Redekop WK2, 1Philips Research Asia, Shanghai, China, 2Erasmus Medical Center, Rotterdam, Netherlandspg 82 PcV15 THE COST-EFFECTIVENESS OF ALISKIREN IN PATIENTS WITH HYPERTENSION : AN ADAPTATION IN KOREA Suh J, Kim S, Novartis, Seoul, South Koreapg 82 PcV16 RELATIONSHIP BETWEEN THE BMI AND HEALTH CARE ExPENDITURES IN SUBJECTS WITH AND WITHOUT CARDIOVASCULAR DISEASE USING THE MEDICAL

eXPeNDITURe PANeL SURVeY Suh HS, Doctor JN, University of Southern California, Los Angeles, CA, USA

monday, 8 September: 8:00am-8:00pm & tueSday, 9 September: 8:00am-6:00pmpoSter author dIScuSSIon hour: monday, 8 September: 6:00pm-7:00pm

28






cARDIOVAScULAR DISORDeRS - Patient-Reported Outcomes Studiespg 82 PcV17 eVALUATION Of QUALITY Of LIfe fOR PATIeNTS ReceIVINg ORAL ANTIcOAgULATION IN TAIWAN chu YW1, Tarn YH2, 1Tri-Service General Hospital, Taipei, Taiwan, 2Center for Drug Evaluation, Taipei, Taiwan

CARDIOVASCULAR DISORDERS - Health Care Use & Policy Studiespg 82 PcV19 THE IMPACT OF U.S. MEDICARE PRESCRIPTION DRUG COVERAGE ON MEDICATION USE PATTERNS AMONG THE ELDERLY Zhang Y, Donohue JM, Lave J, University of Pittsburgh, Pittsburgh, PA, USApg 83 PcV20 A ReTROSPecTIVe eVALUATION Of STATINS UTILIZATION PATTeRN IN Asuphol O1, Chaiyakunapruk N1, Poowaruttanawiwit P1, Jaengim S1, Jeanpeerapong N2, Jedsadayanmata A1, 1Naresuan University, Muang, Phitsanulok, Thai-

land, 2Buddhachinnaraj Hospital, Muang, Phitsanulok, Thailand pg 83 PcV22 UTILIZATION PATTERN OF DRUG ELUTING STENTS(DES), 2004~2007 Song HJ, Shin SY,1Health Insuracne Review & Assessment Service, Seoul, South Koreapg 83 PcV23 COMPARISON OUTCOMES BETWEEN DRUG-ELUTING STENTS AND BARE METAL STENTS: USING AN ADMINISTRATION DATA Shin SY, Song HJ, Health Insurance Review & Assessment Service, Seoul, South Korea pg 83 PcV24 THE CHARACTERISTICS OF PREHOSPITAL CARE OF STROKE PATIENTS IN A SMALL REGION OF WESTERN-HUNGARY AFTER ACCESS TO EU 2005-2007 Betlehem J1, Simon-Horvath L1, Nagy G1, Marton J1, Kriszbacher I1, Sebestyén A2, Oláh A1, Vas g1, Boncz I1, 1University of Pécs, Pécs, Hungary, 2National Health

Insurance Fund Administration, Budapest, Hungarypg 85 PcV25 A LONGITUDINAL STUDY ExPLORING PRACTICE-MAKES-PERFECT EFFECT IN TAIWAN — USING CORONARY ARTERY BYPASS GRAFT AS AN ExAMPLE chang Yc1, Yang MC2, 1Asia University, Taichung, Taiwan, 2National Taiwan University, Taipei, Taiwanpg 84 PcV26 DRUG THERAPY PATTERNS AND CHANGES FOR PATIENTS WITH DIABETES ON ELEVATED TRIGLYCERIDES Ho HY, Livengood K, Ahn J, University of Southern California, Los Angeles, CA, USA

DIABETES/ENDOCRINE DISORDERS - Clinical Outcomes Studiespg 84 PDB1 THE SAFETY OF METFORMIN USE IN TYPE 2 DIABETES PATIENTS WITH HEART FAILURE Pao LH1, Su RY1, Kou CW2, 1National Defense Medical Center, Taipei, Taiwan, 2Cheng Hsin Rehabilitation Medical Center, Taipei, Taiwan

DIABETES/ENDOCRINE DISORDERS - Cost Studiespg 84 PDB2 COST-EFFECTIVENESS ANALYSIS OF VOGLIBOSE IN PREVENTION OF TYPE 2 DIABETES IN JAPANESE WITH IMPAIRED GLUCOSE TOLERANCE (IGT) Ikeda S1, Kobayashi M2, Tajima N3, 1International University of Health and Welfare, Ohtawara, Tochigi, Japan, 2Crecon Research and Consulting Inc, Shibuya-ku,

Tokyo, Japan, 3Jikei University School of Medicine, Minato-ku, Tokyo, Japanpg 84 PDB3 COST-EFFECTIVENESS ANALYSIS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIx INSULIN FOR TYPE 2 DIABETIC PATIENTS IN SAUDI ARABIA Ali M1, White J2, Nielsen S3, Fakhoury W4, Palmer JL5, Valentine WJ5, 1IMS Health, Riyadh, Saudi Arabia, Riyadh, Saudi Arabia, 2Novo Nordisk International

Operations A/S, Zurich, Switzerland, 3Novo Nordisk A/S, Virum, Denmark, 4IMS Health, London, UK, 5IMS Health, Basel, Switzerland pg 85 PDB4 COST-EFFECTIVNESS ANALYSIS OF BIPHASIC INSULIN ASPART IN TYPE 2 DIABETICS IN CHINA: RESULTS FROM AN OBESERVATIONAL STUDY White J1, Lynch M2, Jing L3, 1Novo Nordisk International Operations A/S, Zurich, Switzerland, 2IMS Health, Shanghai, China, 3Novo Nordisk (China) Pharmaceuti-

cals Co. Ltd, Beijing, China pg 85 PDB5 COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIx INSULIN FOR TYPE 2 DIABETIC PATIENTS IN SOUTH KOREA Lee KH1, White J2, Nielsen S3, 1IMS Health, Korea, Seoul, South Korea, 2Novo Nordisk International Operations A/S, Zurich, Switzerland, 3Novo Nordisk A/S,

Virum, Denmark pg 85 PDB6 POSSIBLE COST SAVINGS IN TAIWAN: SELF-MEASUREMENT OF BLOOD GLUCOSE IN TYPE 2 DIABETES PATIENTS (ROSSO STUDY NO. 15) Neeser K1, Weber C1, Kocher S1, Schneider B2, 1Institute for Medical Informatics and Biostatistics, Basel, Switzerland, 2Medical University of Hannover, Han-

nover, Germanypg 85 PDB7 DIRECT MEDICAL COSTS OF TYPE 2 DIABETIC PATIENTS IN THE TERTIARY HOSPITAL Hwang JA1, Park TC1, Jung SH2, Kim HJ1, Kim DJ1, Kim SH3, Nam M3, Kim TH4, Lee MK4, Lee KW1, 1Ajou University School of Medicine, Suwon, South Korea,

2Pochon CHA University, Seoul, South Korea, 3Inha University School of Medicine, Incheon, South Korea, 4Sungkyunkwan University School of Medicine, Seoul, South Korea

pg 85 PDB8 DIRECT MEDICAL COSTS OF TYPE 2 DIABETIC PATIENTS IN KOREA : COST ANAYLSIS FROM THE KOREAN NATIONAL DIABETES PROGRAM Kim HJ1, Kim TH1, Han SJ1, Kim DJ1, Chun KH1, Kim YS2, Woo JT2, Baik SH3, Park YS4, Nam M5, Kim SH6, Ahn K2, Lee KW1, 1Ajou University School of Medicine,

Suwon, South Korea, 2Kyung Hee University College of Medicine, Seoul, South Korea, 3Korea University College of Medicine, Seoul, South Korea, 4Hanyang Uni-versity College of Medicine, Guri, South Korea, 5In Ha University College of Medicine, Incheon, South Korea, 6Kwandong University Collage of Medicine, Seoul, South Korea

pg 86 PDB9 INCREMENTAL TREATMENT COSTS ATTRIBUTABLE TO OBESITY IN PATIENTS WITH DIABETES MELLITUS IN THE U.S. Suh Dc1, Jang EJ1, Kim CM2, Jung JC3, Jang SM4, 1Rutgers University, Piscataway, NJ, USA, 2Catholic University, Seoul, Suhcho-gu, South Korea, 3Korea National

Health Insurance Corporation, Mapo-gu, Seoul, South Korea, 4Health Insurance Review & Assessment Service, Seoul, South Korea


29






DIABETES/ENDOCRINE DISORDERS - Patient-Reported Outcomes Studiespg 86 PDB10 effecT Of ANTIHYPeRgLYceMIc MeDIcATION ADHeReNce ON HOSPITALIZATION AND HeALTH cARe cOST Jang SM1, Park IB2, Suh DC3, Moon KT4, Kim CM5, Kim JY4, 1Health Insurance Review & Assessment Service, Seoul, South Korea, 2Gachon University, Incheon,

South Korea, 3Rutgers University, Piscataway, NJ, USA, 4Health Insurance Review & Assessment Service, Seoul, South Korea, 5Catholic University, Seoul, Suhcho-gu, South Korea

pg 86 PDB12 TRANSFERABILITY OF PATIENT REPORTED-OUTCOMES IN DIABETES: CULTURAL DIFFERENCES IN JAPAN Crawford B1, Palmer S2, Boye KS3, Breugelmans R4, Mear I5, 1Mapi Values, Tokyo, Meguro, Japan, 2Mapi Values, Boston, MA, USA, 3Eli Lilly and Company, India-

napolis, IN, USA, 4Tokyo Medical University, Shinjuku, Tokyo, Japan, 5Mapi Research Institute, Lyon, France

DIABETES/ENDOCRINE DISORDERS - Health Care Use & Policy Studiespg 86 PDB14 INITIAL IMPROVEMENT IN GLYCAEMIC CONTROL AMONGST NEW TYPE 2 DIABETIC PATIENTS govinda Raj A, Toh MP, Heng BH, National Healthcare Group, Singapore, Singapore pg 87 PDB15 DO PATIENTS WITH MULTIPLE CHRONIC CONDITIONS RECEIVE LOWER QUALITY OF CARE? Bae S1, Rosenthal M2, 1Health Insurance Review and Assessment Service, Seoul, South Korea, 2Harvvard School of Public Health, Boston, MA, USA

GASTROINTESTINAL DISORDERS - Health Care Use & Policy Studiespg 87 PgI2 ARE ALL ALGINATES REALLY THE SAME? A COMPARISON OF ALGINATE SWITCHING PATTERNS IN A LARGE LONGITUDINAL UK DATABASE Bhatt A1, Connolly M2, 1Reckitt Benckiser (Healthcare), Hull, UK, 2Global Market Access Solutions, St Prex, Switzerland pg 87 PgI3 VALIDITY OF THE KOREAN VERSION OF THE CHRONIC LIVER DISEASE QUESTIONNAIRE (CLDQ) FOR THE ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE

IN KOREAN PATIENTS WITH CHRONIC HEPATITIS B choi HM1, Kwon SY2, Kim Y1, Koo HW1, Choi W1, Lee YS1, Lee YS3, Lee JH4, Lee CH2, 1GlaxoSmithKline, Seoul, South Korea, 2Konkuk University, Seoul, South Korea,

3Catholic University of Korea, Bucheon, South Korea, 4Sungkyunkwan University, Seoul, South Korea

HEALTH CARE USE & POLICY STUDIES - Consumer Role in Health Carepg 87 PHP1 ASSOCIATION BETWEEN DIRECT-TO-CONSUMER ADVERTISING (DTCA) AND DRUG UTILIZATION IN THE U.S. MEDICAID MARKET FOR SELECTED DRUG CLASSES Sheridan J1, guo JJ2, Kelton CM2, Shelly D3, 1Medpace Reference Laboratories, Cincinnati, OH, USA, 2University of Cincinnati, Cincinnati, OH, USA, 3Meridian Life

Science, Inc, Cincinnati, OH, USA

HEALTH CARE USE & POLICY STUDIES - Drug/Device/Diagnostic Use & Policypg 88 PHP2 KOREAN ExPERIENCE OF UTILIZING MEDICAL MATERIALS Song HJ, Shin SY, Health Insuracne Review & Assessment Service, Seoul, South Korea pg 88 PHP3 ESTIMATION OF FINANCIAL BURDEN DUE TO OVER POSSESSION OF CHRONIC DISEASE MEDICATIONS chaiyakunapruk N1, Thanarungroj A1, Cheewasithirungrueng N1, Nimpitakpong P1, Jeanpeerapong N2, Meepadung J2, Srisupha-olarn W3, 1Naresuan University,

Muang, Phitsanulok, Thailand, 2Buddhachinnaraj Hospital, Muang, Phitsanulok, Thailand, 3Naresuan University Phayao, Muang, Phayao, Thailandpg 88 PHP4 ARE KEY INFORMANTS’ OPINIONS ABOUT DRUG SAMPLES CONCORDANT WITH THEIR WISH LIST FOR A NEW DISTRIBUTION SYSTEM? Kyle GJ, Nissen LM, Tett SE, The University of Queensland, St Lucia, QLD, Australiapg 88 PHP5 MOVING TOWARDS EVIDENCE BASED MEDICINE AS A PLATFORM FOR THE REIMBURSEMENT OF PROSTHESES IN AUSTRALIA Glase KM, O’Leary BA, Covance Pty Ltd, Sydney, NSW, Australiapg 88 PHP6 REVIEW OF ALCOHOL POLICIES AND CONTRIBUTIONS FROM KEY PLAYERS IN REDUCING ALCOHOL CONSUMPTION BETWEEN 1997-2007 IN THAILAND Yothasamut J1, Youngkong S1, Teerawattananon Y1, Tantivess S1, Thavorncharoensap M1, Chaikledkaew U2, Lertpitakpong C1, Mohara A1, Kingkaew P1, Yamabhai I1,

1Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand, 2Faculty of Pharmacy Mahidol University, Ratchathewi, Bangkok, Thailand pg 89 PHP7 EVALUATING A GENERIC FIRM’S INCENTIVES TO CHALLENGE THE PATENTS OF AN ORIGINATOR DRUG: LEGISLATIVE CHANGE, PATENT CONDITIONS, AND

MARKET SIZE Rhee J, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea pg 89 PHP8 HERB/DIETARY SUPPLEMENT AND PRESCRIPTION DRUG USE TRENDS AMONG US ADULTS, 1999-2004 Lin HW1, Wittenberg RD2, Shaw JW2, Tsai HH3, Pickard AS4, 1China Medical University, Taichung, Taiwan, 2University of Illinois at Chicago, Chicago, IL, USA,

3China Medical University, Taichung, Taiwan, Changhua City, Changhua County, Taiwan, 4College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA pg 89 PHP9 UTILIZATION OF ERYTHROPOIESIS-STIMULATING AGENTS IN CRITICAL CARE SETTING IN U.S HOSPITALS: A RETROSPECTIVE STUDY Lee SP1, Holdford D2, Brophy GM2, Brophy DF2, Brophy DF2, 1Thomas Jefferson University, Philadelphia, PA, USA, 2Virginia Commonwealth University School of

Pharmacy, Richmond, VA, USA pg 89 PHP10 HOW THE BLIND COPE WITH PROBLEMS OF MEDICINE UTILIZATION Riewpaiboon A, Faculty of Pharmacy Mahidol University, Ratchathevi, Bangkok, Thailandpg 90 PHP11 PRINCIPAL COMPONENTS ANALYSIS OF DRUG UTILIZATION AND ExPENDITURE TRENDS FOR MAJOR THERAPEUTIC CLASSES IN U.S. MEDICAID PROGRAMS Jing Y1, Nguyen K1, Fan H2, Kelton CM1, Li X3, guo JJ1, 1University of Cincinnati, Cincinnati, OH, USA, 2Covance Inc, Sun Prairie, WI, USA, 3UC, 121212, NJ, USA


30

pg 88






HEALTH CARE USE & POLICY STUDIES - Disease Managementpg 90 PHP12 ROAD TRAffIc INJURY AND ITS PReVeNTION IN MONgOLIA Munkhtuvshin O, National Center for Health Development, Ulaanbaatar, Mongolia

HEALTH CARE USE & POLICY STUDIES - Equity and Accesspg 90 PHP13 HEALTH RISK DISTRIBUTION BY SOCIO-ECONOMIC STATUS AND EDUCATIONAL LEVELS OF THAI HOUSEHOLDS: WHO SMOKE AND DRINK MORE? chokevivat V1, Limwattananon S2, Bundhamcharoen K3, Prakongsai P3, Tangcharoensathien V4, 1The Government Pharmaceutical Organisation Board, Bangkok,

Bangkok, Thailand, 2Khon Kaen University, Khon Kaen, Thailand, 3International Health Policy Program (IHPP), Nonthaburi, Thailand, 4International Health Policy Program - Thailand, Nonthaburi, Thailand

HEALTH CARE USE & POLICY STUDIES - Health Care Costs & Managementpg 90 PHP14 INPATIeNT LeNgTH Of STAY AND TOTAL cOSTS Of ILLNeSSeS Of PReSSINg cONceRN fOR ASIAN-AMeRIcAN AND PAcIfIc ISLANDeR WOMeN IN THe

UNITeD STATeS Candrilli SD1, Davis KL2, Balkrishnan R1, 1The Ohio State University, Columbus, OH, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA pg 91 PHP15 IRREGULAR WORKER AND HEALTH ExPENDITURE IN KOREA Park eJ, Korea Institute for Health and Social Afffairs, Seoul, South Koreapg 91 PHP16 THE SOCIOECONOMIC COST OF ILLNESS IN KOREA: 2001~2005 Jung YH, Korea Institute for Health and Social Affairs, Seoul, South Koreapg 91 PHP17 BALANCING THE BUDGET OF THE HUNGARIAN NATIONAL HEALTH INSURANCE FUND ADMINISTRATION (OEP) IN 2007 Boncz I1, Sebestyén A2, Ágoston I1, Vas g1, Gulácsi L3, Betlehem J1, Oláh A1, Kriszbacher I1, 1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund

Administration, Budapest, Hungary, 3Corvinus University of Budapest, Budapest, Hungary pg 91 PHP18 CHALLENGING THE $50,000 THRESHOLD: ADJUSTMENT OF THE COST-EFFECTIVENESS THRESHOLD BY COUNTRY SPECIFIC FACTORS. THE ExAMPLE OF THE

ASIA-PAcIfIc RegION Weber C, Neeser K, Institute for Medical Informatics and Biostatistics, Basel, Switzerlandpg 91 PHP19 FINANCING HEALTH PROMOTION IN SOUTHEAST ASIA– DOES IT MATCH WITH CURRENT AND FUTURE CHALLENGES? Prakongsai P1, Bundhamcharoen K1, Tisayatikom K2, Tangcharoensathien V2, 1International Health Policy Program (IHPP), Nonthaburi, Thailand, 2International

Health Policy Program - Thailand, Nonthaburi, Thailand pg 92 PHP20 COST OF OUT PATIENTS CARE AT THE BASIC HEALTH UNITS IN PAKISTAN (NORTH WEST FRONTIER PROVINCE AND TRIBAL AREAS) DURING 2005 Malik AM, Aga Khan Univeristy, Karachi, Pakistan pg 92 PHP21 ECONOMIC-BASED OUTCOMES ASSESSMENT OF PHARMACEUTICAL CARE IN A UNIVERSITY HOSPITAL MEDICAL INTENSIVE CARE UNIT IN TAIWAN Huang cY1, Hao HS2, Tsai HY2, Hsieh YW1, 1China Medical University Hospital, Taichung, Taiwan, 2China Medical University, Taichung, Taiwanpg 92 PHP23 ESTABLISHMENT OF HUMAN STEM CELL LINES WITH CELL PERMEABLE NANOG AND OCT4 (CP-NANOG AND CP-OCT4) Kang W, Ahn TY, Jo D, Chonnam National University Medical School, Gwangju, South Korea pg 92 PHP24 RACIAL/ETHNIC DIFFERENCES IN THE HEALTH CARE ATTITUDES, PRACTICE OF COST-CUTTING STRATEGIES, AND SOURCES OF HEALTH CARE INFORMATION Stankus AP, Saluja P, Consumer Health Sciences International, Princeton, NJ, USApg 92 PHP25 PREFERENCES FOR DRUG REIMBURSEMENT CRITERIA IN SOUTH KOREA USING DISCRETE CHOICE ExPERIMENTS Lim MK1, Bae EY2, 1Health Insurance Review & Assessment Service, Seoul, South Korea, 2Sangji University, Gangwondo, South Koreapg 93 PHP26 COST RECOVERY OF MEDICAL REHABILITATION SERVICES UNDER THE UNIVERSAL HEALTH COVERAGE SCHEME AT UDONTHANI HOSPITAL Pattanaphesaj J1, Riewpaiboon A2, Riewpaiboon W3, Muenpol P4, Paileeklee S4, Tungjaroen D4, Krutjaikla B4, 1Health Intervention and Technology Assessment

Program (HITAP), Nonthaburi, Thailand, 2Faculty of Pharmacy Mahidol University, Ratchathevi, Bangkok, Thailand, 3Sirindhorn National Medical Rehabilitation Center, Nonthaburi, Thailand, 4Udonthani Hospital, Udonthani, Thailand

pg 93 PHP27 THE EFFECT OF THE PERFORMANCE VOLUME LIMIT (PVL) ON THE PATIENT ADMISSIONS OF THE HUNGARIAN HOSPITALS Boncz I1, Sebestyén A2, Ágoston I1, Nagy Z3, Vas g1, Gulácsi L4, Oláh A1, Betlehem J1, Kriszbacher I1, 1University of Pécs, Pécs, Hungary, 2National Health Insurance

Fund Administration, Budapest, Hungary, 3Health Insurance Supervisory Authority, Budapest, Hungary, 4Corvinus University of Budapest, Budapest, Hungary pg 93 PHP28 UTILITIES ARE NOT ALL THE SAME – HOW REIMBURSEMENT AGENCIES VARY IN THEIR DESIRE FOR UTILITIES Lloyd A, Oxford Outcomes, Oxford, UK

HEALTH CARE USE & POLICY STUDIES - Health Care Research & Educationpg 93 PHP30 PROTEIN-BASED NEW DRUG DISCOVERY/DEVELOPMENT USING MACROMOLECULE INTRACELLULAR TRANSDUCTION TECHNOLOGY (MITT) Jo D, ProCell Therapeutics, Inc./Chonnam National University Medical School, Gwangju, South Korea


31






HEALTH CARE USE & POLICY STUDIES - Prescribing Behavior & Treatment Guidelinespg 93 PHP31 THE PRESCRIBING OF CHINESE HERBAL PRODUCTS IN TAIWAN: A CROSS-SECTIONAL ANALYSIS OF THE NATIONAL HEALTH INSURANCE REIMBURSEMENT

DATABASE Hsieh Sc1, Lee CF2, Wang JD3, 1Center for Drug Evaluation, Taipei City, Taiwan, 2Tri-Service General Hospital, Taipei, Taiwan, 3National Taiwan University, Taipei, Taiwan

HEALTH CARE USE & POLICY STUDIES - Regulation of Health Care Sectorpg 94 PHP32 INTRODUCTION OF HEALTH-ECONOMICS INTO GOVERNMENTAL DECISION-MAKING ON DRUG REIMBURSEMENT IN HUNGARY Nagy Z1, Sebestyén A2, Vas g3, Ágoston I3, Kriszbacher I3, Oláh A3, Boncz I3, 1Health Insurance Supervisory Authority, Budapest, Hungary, 2National Health Insur-

ance Fund Administration, Budapest, Hungary, 3University of Pécs, Pécs, Hungarypg 94 PHP33 OVeRVIeW AND cOMPARISON Of DRUg SAfeTY SURVeILLANce IN DeVeLOPINg cOUNTRIeS guo JJ1, Vaidya S1, Jing Y1, Du W2, 1University of Cincinnati, Cincinnati, OH, USA, 2Shanghai Food Drug & Administration, Shanghai, Shanghai, China pg 94 PHP34 COMPARING THE LEGAL BACKGROUND OF HOSPITAL BED REDUCTION IN HUNGARY IN 1996 AND IN 2007 Ágoston I1, Sebestyén A2, Nagy Z3, Vas g1, Kriszbacher I1, Boncz I1, 1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund Administration, Buda-

pest, Hungary, 3Health Insurance Supervisory Authority, Budapest, Hungary pg 94 PHP35 THE EFFECT OF CURRENT (2007) HEALTH CARE REFORMS ON THE NUMBER OF HOSPITAL BEDS IN HUNGARY Vas g1, Sebestyén A2, Ágoston I1, Nagy Z3, Kriszbacher I1, Betlehem J1, Vas B1, Boncz I1, 1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund

Administration, Budapest, Hungary, 3Health Insurance Supervisory Authority, Budapest, Hungary

INDIVIDUAL’S HEALTH - Clinical Outcomes Studiespg 95 PIH1 cOMPAReTIVe effecTIVeNeSS AND SAfeTY Of TWO MONOPHASIc ORAL cONTRAcePTIVeS Of MARVeLON AND MINULeT Wang L1, Peng L1, Li Y2, 1Sichuan University, Chengdu, Sichuan, China, 2West China Hospital, Sichuan University, Chengdu, China

INDIVIDUAL’S HEALTH - Cost Studiespg 95 PIH2 BUDGET IMPACT OF THE THALASSEMIA MANAGEMENT UNDER THE NATIONAL HEALTH SECURITY SCHEME Bunyadharokul S1, Riewpaiboon A2, Chaikledkaew U3, Torcharus K4, 1Mahidol University, Ratchathewi District, Bangkok, Thailand, 2Faculty of Pharmacy Mahidol

University, Ratchathewi, Bangkok, Thailand, 3Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand, 4Phramongkutklao Hospi-tal, Ratchathewi, Bangkok, Thailand

pg 95 PIH3 ecONOMIc eVALUATION Of 7-VALeNT PNeUMOcOccAL cONJUgATe VAccINe IN TAIWAN: A cOST-effecTIVeNeSS ANALYSIS Of UNIVeRSAL INfANT VAccINATION

Wu D1, Rinaldi F2, Huang YC3, Chang CJ4, 1Department of Biological Statistics, Institute of Public Health, National Yang-Min University, Taipei, Taiwan, 2Wyeth Australia Pty. Ltd, Sydney, NSW, Australia, 3Department of Pediatrics, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, 4Graduate Institute of Clinical Medical Sciences,Chang Gung University, Taoyuan, Taiwan

pg 95 PIH4 eSTIMATINg THe TReATMeNT cOSTS Of MeNOPAUSe-ReLATeD SYMPTOMS IN TAIWAN Huang SY, Tang CH, Hung ST, Chow I, Chang CL, Liao CH, Taipei Medical University, Taipei, Taiwan

INDIVIDUAL’S HEALTH - Patient-Reported Outcomes Studiespg 96 PIH5 QUALITY OF LIFE IN TRANSFUSION DEPENDENT THALASSAEMIA PATIENTS ON DESFERRIOxAMINE TREATMENT AT HOSPITAL UNIVERSITI KEBANGSAAN

MALAYSIA AND HOSPITAL KUALA LUMPUR Dahlui M1, Aljunid SM2, Ibrahim HS3, 1University Malaya, Kuala Lumpur, Malaysia, 2Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia, 3Paediatric Intitute,

Kuala Lumpur, Malaysia pg 96 PIH6 THE IMPACT OF HEALTH STATE SELECTION ON EQ-5D VALUATION - A STUDY BASED ON KOREAN VALUATION SET chuang LH1, Nam HS2, Kind P1, 1University of York, York, UK, 2College of Medicine, Chungnam National University, Daejeon, South Korea

INfecTION - clinical Outcomes Studiespg 96 PIN1 ANTIBIOTIC IMPACT ON HOSPITAL LENGTH OF STAY AND COSTS AMONG INPATIENT COMMUNITY ACQUIRED PNEUMONIA (CAP) PATIENTS Ye X1, Sikirica V2, Benson C3, Doshi D4, Schein JR3, Raut M3, Riedel AA1, 1i3 Innovus, An Ingenix Company, Eden Prairie, MN, USA, 2ETHICON, Inc, Somerville, NJ,

USA, 3Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 4Ortho-McNeil Janssen Scientific Affairs, LLC, San Diego, CA, USApg 97 PIN2 EFFECTIVENESS AND SAFETY OF ZIDOVUDINE FOR PREVENTING THE RISK OF MOTHER-TO-CHILD TRANSMISSION OF HIV: A SYSTEMATIC REVIEW Wang L1, Li Y2, Sun X2, 1Sichuan University, Chengdu, Sichuan, China, 2West China Hospital, Sichuan University, Chengdu, China pg 97 PIN3 EFFECTIVENESS AND SAFETY OF NEVIRAPINE FOR PREVENTING THE RISK OF MOTHER-TO-CHILD TRANSMISSION OF HIV: A SYSTEMATIC REVIEW Wang L1, Li Y2, 1Sichuan University, Chengdu, Sichuan, China, 2West China Hospital, Sichuan University, Chengdu, China

INfecTION - cost Studiespg 97 PIN4 cOST-effecTIVeNeSS Of VAccINATION AgAINST SeASONAL INfLUeNZA: A ReALISTIc-Age-STRUcTUReD DeTeRMINISTIc cOMPARTMeNTAL MODeL Thompson WA1, Eggington SG1, Tucker D2, 1IMS Health, London, UK, 2GlaxoSmithKline Biologicals, Wavre, Belgium


32






pg 98 PIN5 ecONOMIc eVALUATION Of ROUTINe 7-VALeNT PNeUMOcOccAL cONJUgATe VAccINATION Of INfANTS IN THe ASIA-PAcIfIc: LeSSONS LeARNeD fROM HONG KONG, SINGAPORE AND TAIWAN

Rinaldi f, Wyeth Australia Pty. Ltd, Sydney, NSW, Australiapg 98 PIN6 COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION OF THE ELDERLY: A STUDY USING NATIONAL HEALTH INSURANCE DATABASE IN SOUTH KOREA, 2005 Kim SA1, Lee SY2, Batmunkh N3, Kilgore PE3, Ki MR4, 1International Vaccine Institute; Graduate School of Public Health, Seoul National University, Seoul, South

Korea, 2Health Insurance Research Center, Seoul, South Korea, 3International Vaccine Institute, Seoul, South Korea, 4Eulji University School of Medicine, Dae-jeon, South Korea

pg 98 PIN7 cOST-effecTIVeNeSS ANALYSIS Of OSeLTAMIVIR fOR INfLUeNZA IN JAPAN: MODeLINg IN THe VIRUS eMeRgINg ReSISTANT TO THe DRUg Nagase H1, Kamae M2, Moriwaki K3, Yanagisawa S3, Kamae I4, 1Kobe University School of Medicine, Kobe, Hyogo, Japan, 2Tufts-NEMC, U.S.A, Boston, MA, USA,

3Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan, 4Kobe University Graduate School of Medicine, Kobe, Japanpg 98 PIN8 ECONOMIC EVALUATION OF DIFFERENT TREATMENTS OF CHRONIC HEPATITIS B IN CHINA Lacey L1, Lu XZ2, Tan-Mulligan A3, 1LaceySolutions Ltd, Dublin County, Ireland, 2GlaxoSmithKline, Shanghai, China, 3GlaxoSmithKline China, Shanghai, Chinapg 99 PIN9 AN ECONOMIC EVALUATION OF THE POTENTIAL IMPACT OF EMERGING VACCINE TECHNOLOGIES ON MEASLES COST AND DISEASE BURDEN IN TWO ASIAN

SeTTINgS garrison L1, Bauch CT2, Bresnahan B1, Hazlet TK1, Kadiyala S1, Veenstra DL1, 1University of Washington, Seattle, WA, USA, 2University of Guelph, Guelph, ON, Canada pg 99 PIN10 MONOTHERAPY VERSUS COMBINATION THERAPY IN INTRA-ABDOMINAL INFECTIONS: COST-EFFECTIVENESS STUDY FROM INDIA Kochhar P1, Suvarna V1, Duttagupta S2, Sarkar S1, 1Pfizer India, Mumbai, India, 2Pfizer Inc, New York, NY, USApg 99 PIN11 ECONOMIC EVALUATION OF TREATMENT ADMINISTRATION STRATEGIES OF GANCICLOVIR FOR CYTOMEGALOVIRUS RETINITIS IN HIV/AIDS PATIENTS IN

THAILAND Teerawattananon K, Health Intervention and Technology Assessment Program (HITAP), Muang, Nonthaburi, Thailandpg 99 PIN12 A COST MINIMIZATION ANALYSIS COMPARING DIFFERENT ANTIBIOTIC REGIMENS USED IN TREATING PNEUMONIA IN HONG KONG Lee KK, Chau MW, Fan BS, Wan MH, Lee VWY, The Chinese University of Hong Kong, Shatin, Hong Kongpg 99 PIN13 THE CLINICAL AND ECONOMIC BURDEN OF ROTAVIRUS INFECTION IN KOREA Yang BM1, Jo DS2, Kim YH1, Hong JM1, Kim JS2, 1Seoul National University, Seoul, South Korea , 2Chonbuk National University, Jeonju, Koreapg 100 PIN15 MEDICAL COST OF BACTEREMIC PNEUMOCOCCAL PNEUMONIA AND NON-BACTEREMIC PNEUMOCOCCAL PNEUMONIA FOR HOSPITALIZED PATIENTS IN

KOREA, 2002-2005 Kim SA1, Lee SY2, Batmunkh N3, Kilgore PE3, Ki MR4, 1International Vaccine Institute; Graduate School of Public Health, Seoul National University, Seoul, South

Korea, 2Health Insurance Research Center, Seoul, South Korea, 3International Vaccine Institute, Seoul, South Korea, 4Eulji University School of Medicine, Dae-jeon, South Korea

INFECTION - Health Care Use & Policy Studiespg 100 PIN16 EFFECT OF DISEASE AWARENESS COMMUNICATION OF HUMAN PAPILLOMAVIRUS (HPV) VACCINE ON PUBLIC PERCEPTIONS AND VACCINATION DECISION Putchong c1, Udomsook K1, Sumpradit N2, Khanabkaew K2, Teerawattananon Y1, 1Health Intervention and Technology Assessment Program (HITAP), Nonthaburi,

Thailand, 2Food and Drug Administration, Nonthaburi, Thailandpg 100 PIN17 OUTPATIENT ANTIBIOTIC CONSUMPTION TRENDS IN FIVE MUNICIPAL WARDS OF DELHI, INDIA Kotwani A1, Holloway K2, RoyChaudhury R3, 1V.P.Chest Institute, Delhi, India, 2World Health Organisation, Geneva, Switzerland, 3Indraprastha Apollo Hospitals,

New Delhi, India

CONCEPTUAL PAPERS & RESEARCH ON METHODS - Cost Methodspg 100 PMc1 TOWARD AN ADAPTeD RefeReNce cASe fOR DeVeLOPINg cOUNTRIeS: INcORPORATINg DONOR fUNDINg IMPAcTS IN cOST-effecTIVeNeSS ANALYSIS gauvreau cL1, Ungar WJ2, Cohen-Kohler JC1, 1University of Toronto, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada

CONCEPTUAL PAPERS & RESEARCH ON METHODS - Databases & Management Methodspg 101 PMc2 DEVELOPMENT OF THAI HEALTH TECHNOLOGY ASSESSMENT DATABASE Maitreemit P, Sribundit N, Silpakorn University, Nakornpathom, Nakornpatom, Thailand

CONCEPTUAL PAPERS & RESEARCH ON METHODS - Patient-Reported Outcomes Studiespg 101 PMC3 HEALTH STATES VALUES IN THE THAI GENERAL POPULATION: WHAT FACTORS INFLUENCE THE RATE OF INCONSISTENT RESPONSES? Tongsiri S1, Cairns JA2, 1London School of Hygiene and Tropical Medicine, London, UK, 2London School of Hygiene and Tropical Medicine, London, UKpg 101 PMc4 KOREAN VALUATION OF EQ-5D HEALTH STATES USING TIME TRADE OFF METHOD Nam HS1, Lee YK2, Kim KY1, Kweon IS1, Kind P3, Chuang LH3, Kweon SS4, Yang HK1, 1Chungnam National University, Daejeon, South Korea, 2Korea Centers for Dis-

ease Control and prevention, Seoul, South Korea, 3University of York, York, UK, 4Chonnam National University Hwasun Hospital, Chonnam province, South Korea


33






pg 101 PMc5 QUALITY Of LIfe MeASUReMeNT IN cURReNT cLINIcAL TRIALS: fOcUS ON cHRONIc DISeASeS Bhanderi M, Singh N, Kumar R, Chawla A, Sehgal M, Heron Health Private Ltd, Chandigarh, Indiapg 102 PMc6 IS UTILITY A LINEAR FUNCTION OF LONGEVITY? Knoph Kvamme M, Kristiansen IS, University of Oslo, Oslo, Norway

CONCEPTUAL PAPERS & RESEARCH ON METHODS - Study & Methods Design pg 102 PMc7 A BAYESIAN ADAPTIVE DESIGN FOR EVALUATION OF THE GAP BETWEEN EFFICACY AND ERROR-ADJUSTED EFFECTIVENESS Moriwaki K1, Kamae I2, Yanagisawa S1, Nagase H3, 1Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan, 2Keio University Graduate School of

Health Management, Fujisawa, Kanagawa, Japan, 3Kobe University School of Medicine, Kobe, Hyogo, Japan pg 102 PMc8 eSTIMATINg A SOcIeTAL VALe fOR A ceILINg THReSHOLD IN THAILAND: A cASe STUDY Of MeASURINg WILLINgeSS-TO-PAY PeR QUALITY- ADJUSTeD

LIfe YeAR Thavorncharoensap M, Natanant S, Kulpeng W, Teerawattananon Y, Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand pg 102 PMc9 BIAS OF INDIRECT COMPARISON META-ANALYSIS WHEN USING RATIO AS EFFECT MEASUREMENT Shau WY1, Hsieh Sc2, 1Center for Drug Evaluation, Taipei, Taipei, Taiwan, 2National Taiwan University College of Public Health, Taipei City, Taiwan

MeNTAL HeALTH - clinical Outcomes Studiespg 102 PMH1 EFFICACY, SAFETY AND RESOURCE USE IN PATIENTS SWITCHED DIRECTLY TO RISPERIDONE MICROSPHERES: EVIDENCE FROM CHINESE SAMPLES Li Hc1, Gu NF2, Dong P3, 1China Pharmaceutical University, Nanjing, Jiangsu, China, 2Shanghai Mental Health Center, Shanghai, Shanghai, China, 3Xi’an-Janssen

Pharmaceutical Ltd, Beijing, Beijing, China

MeNTAL HeALTH - cost Studiespg 103 PMH2 COST ANALYSIS BETWEEN VALPROATE AND LITHIUM IN THE MANAGEMENT OF BIPOLAR DISORDER: RESULTS FROM A MULTINATIONAL STUDY (VALID

STUDY – VALPROATE VERSUS LITHIUM IN BIPOLAR DISORDERS) Li Sc1, Nguyen T2, 1University of Newcastle, Callaghan, Australia, 2Sanofi-Aventis, Paris, Francepg 103 PMH3 cOST-effecTIVeNeSS Of eScITALOPRAM cOMPAReD TO VeNLAfAXINe AND fLUVOXAMINe IN THe TReATMeNT Of MAJOR DePReSSIVe DISORDeR IN

SINgAPORe Xie F1, Despiégel N2, Danchenko N2, Hansen K2, 1McMaster University, Hamilton, Ontario, Canada, 2Lundbeck SAS, Paris, Francepg 103 PMH4 ECONOMIC ASSESSMENT OF THREE COMMONLY USED ANTIPSYCHOTIC AGENTS IN THE PUBLIC SECTOR OF HONG KONG USING A DECISION ANALYTIC

MODeL Lee KK, Lee VWY, The Chinese University of Hong Kong, Shatin, Hong Kongpg 103 PMH5 COST-EFFECTIVENESS ANALYSIS OF FLUVOxAMINE IN THE TREATMENT OF SOCIAL ANxIETY DISORDER (SAD) Makino K, Kamei M, Showa University, Shinagawa, Tokyo, Japan pg 104 PMH6 cOST effecTIVeNeSS Of LONg-AcTINg RISPeRIDONe INJecTION VeRSUS ALTeRNATIVe ATYPIcAL ANTIPSYcHOTIc AgeNTS IN PATIeNTS WITH ScHIZO-

PHReNIA IN cHINA Li M1, Yang L2, Tao L2, Dong P3, 1Suzhou Guangji Hospital, Su Zhou, Jiang Su, China, 2Peking University, Beijing, Beijing, China, 3Xian-Janssen Pharmaceutical Ltd,

Beijing, Beijing, China pg 104 PMH7 ECONOMIC EVALUATION OF PALIPERIDONE ER IN THE TREATMENT OF PATIENTS WITH AN ACUTE ExACERBATION OF SCHIZOHPHRENIA IN KOREA Suh gH, Hallym University Medical Center Hangang Sacred Heart Hospital, Seoul, South Koreapg 104 PMH8 ECONOMIC AND CLINICAL CONSEQUENCES ASSOCIATED WITH POTENTIAL DRUG-DRUG INTERACTIONS BETWEEN ANTIPSYCHOTICS AND CONCOMITANT

MeDIcATIONS IN PATIeNTS WITH ScHIZOPHReNIA guo JJ1, Kelton CM1, Patel NC2, Wu JH3, Jing Y1, Fan H4, Keck P1, 1University of Cincinnati, Cincinnati, OH, USA, 2University of Georgia, Augusta, GA, USA, 3Ortho-

McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 4Covance Inc, Sun Prairie, WI, USA pg 104 PMH9 ECONOMIC COSTS OF ALCOHOL-RELATED ABSENTEEISM AND PRESENTEEISM IN THAILAND Thitiboonsuwan K1, Lertpitakpong C1, Yothasamut J1, Thavorncharoensap M1, Teerawattananon Y1, Chaikledkaew U2, 1Health Intervention and Technology As-

sessment Program (HITAP), Nonthaburi, Thailand, 2Faculty of Pharmacy Mahidol University, Ratchathewi, Bangkok, Thailand pg 105 PMH10 ECONOMIC IMPACT ON HEALTH CARE COST DUE TO ALCOHOL DRINKING AMONG THAI POPULATION Neramitpitagkul P1, Lertpitakpong C1, Yothasamut J1, Thavorncharoensap M1, Chaikledkaew U2, Teerawattananon Y1, 1Health Intervention and Technology As-

sessment Program (HITAP), Nonthaburi, Thailand, 2Faculty of Pharmacy Mahidol University, Ratchathewi, Bangkok, Thailand pg 105 PMH11 THE COSTS OF ALZHEIMER’S DISEASE TREATMENT IN TAIWAN chan ALf, Chimei medical center, Tainan, Taiwanpg 105 PMH12 TREATMENT COST AND COMORBIDITIES ASSOCIATED WITH OBESITY AMONG MEDICAID PATIENTS WITH BIPOLAR DISORDER guo JJ1, Kelton CM1, Jing Y1, Patel NC2, 1University of Cincinnati, Cincinnati, OH, USA, 2University of Georgia, Augusta, GA, USA


34






pg 105 PMH13 A COMPARISION OF HEALTH CARE UTILIZATION AND COST OF CHILDREN AND ADOLESCENTS WITH BIPOLAR DISORDER TREATED WITH ATYPICAL ANTIPSY-CHOTIC MONOTHERAPY VERSUS MOOD STABILIZER MONOTHERAPY

Jing Y1, Guo JJ1, Patel NC2, Heaton PC1, Li H3, Kelton CM1, 1University of Cincinnati, Cincinnati, OH, USA, 2University of Georgia, Augusta, GA, USA, 3Bristol-Myers Squibb Company, Singapore, Singapore

MENTAL HEALTH - Health Care Use & Policy Studiespg 105 PMH14 effIcAcY AND SAfeTY Of ORAL ATYPIcAL ANTIPSYcHOTIcS fOR ScHIZOPHReNIA: A MeTA-ANALYSIS INcLUDINg PALIPeRIDONe eXTeNDeD-ReLeASe Jones MP1, Nicholl D2, Trakas K3, 1Macquarie University, North Ryde, NSW, Australia, 2Johnson & Johnson, Raritan, NJ, USA, 3Johnson & Johnson, Toronto, ON,

Canadapg 106 PMH15 ANALYSIS OF POTENTIAL DRUG-DRUG INTERACTION PAIRS ASSOCIATED WITH ANTIPSYCHOTICS AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA,

SCHIZOAFFECTIVE DISORDER, OR BIPOLAR DISORDER guo JJ1, Patel NC2, Jing Y1, Kelton CM1, Fan H3, Keck P1, 1University of Cincinnati, Cincinnati, OH, USA, 2University of Georgia, Augusta, GA, USA, 3Covance Inc,

Sun Prairie, WI, USApg 106 PMH16 CHANGES OF HOSPITAL SERVICE USE IN SCHIZOPHRENIA PATIENTS TREATED WITH LONG-ACTING INJECTABLE RISPERIDONE: A ONE-YEAR MIRROR IMAGE

STUDY USING A POPULATION-BASED DATABASE IN TAIWAN chang Hc1, Tang CH1, Su KP2, Tsai SJ3, Yen FC4, Chang CL1, Hung ST1, 1Taipei Medical University, Taipei, Taiwan, 2China Medical University Hospital, Taichung,

Taiwan, 3Taipei Veterans General Hospital, Taipei, Taiwan, 4Cheng-Hsin Rehabilitation Medical Center, Taipei, Taiwanpg 106 PMH17 OFF-LABEL USE OF SECOND-GENERATION ANTIPSYCHOTICS AMONG ADULT PATIENTS WITH BIPOLAR DISORDER IN A LARGE MANAGED CARE POPULATION Demland JA, guo JJ, Kelton CM, Jing Y, Wigle PR, University of Cincinnati, Cincinnati, OH, USA

MUSCULAR-SKELETAL DISORDERS - Clinical Outcomes Studiespg 107 PMS1 EFFICACY AND GASTROINTESTINAL SAFETY OF CELECOxIB COMPARING TO OTHER NSAIDS: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS Lee J1, Park S2, Lee J3, Ko S4, 1Korea University, Seoul, South Korea, 2Yonsei university, Seoul, South Korea, 3Seoul National University, Seoul, South Korea, 4Pfizer

Korea, Seoul, South Koreapg 107 PMS2 THE ROLE OF RISK FACTORS IN MORTALITY AFTER FEMORAL NECK FRACTURE Sebestyén A1, Boncz I2, Sándor J2, Nyárády J2, Betlehem J2, Oláh A2, Vas g2, Tóth F2, 1National Health Insurance Fund Administration, Budapest, Hungary, 2Univer-

sity of Pécs, Pécs, Hungary

MUSCULAR-SKELETAL DISORDERS - Cost Studiespg 107 PMS3 COST-BENEFIT ANALYSIS OF MANAGEMENT STRATEGIES TO REDUCE MOTORCYCLE ROAD TRAFFIC INJURIES Srijariya W, Riewpaiboon A, Chaikledkaew U, Pongcharoensuk P, Faculty of Pharmacy Mahidol University, Ratchathewi, Bangkok, Thailand pg 107 PMS4 COST-EFFECTIVENESS ANALYSIS OF RITUxIMAB FOR RHEUMATOID ARTHRITIS IN TAIWAN Lin HY1, Chang DM2, Chen DY3, Cheng TT4, Huang CM5, Lou SF6, Su CC7, Tsai WC8, Tseng JC9, Wei CC10, Yang L11, Hazard S12, 1Taipei Veterans General Hospital,

Taipei, Taiwan, 2Tri-service General Hospital, Taipei, Taiwan, 3Taichung Veterans General Hospital, Taichung, Taiwan, 4Chang Gung Memorial Hospital, Koushung, Taiwan, 5China Medical University Hospital, Taichung, Taiwan, 6Chang Gung Memorial Hospital, Linkou, Taiwan, 7Changhua Christian Hospital, Changhua, Taiwan, 8Kaoshiung Medical University Hospital, Kaoshiung, Taiwan, 9Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, 10Chung Shan Medical University Hospi-tal, Taichung, Taiwan, 11Roche Products Ltd, Taipei, Taiwan, 12F. Hoffmann-La Roche AG, Basel, Switzerland

pg 108 PMS5 ecONOMIc eVALUATION ON ScReeNINg STRATegIeS AND TReATMeNT OPTIONS fOR POSTMeNOPAUSAL OSTeOPOROSIS Kingkaew P1, Maleewong U2, Ngarmukos C3, Teerawattananon Y1, 1Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand,

2Mahasarakham University, Mahasarakham, Thailand, 3Ramathibodi Hospital, Bangkok, Thailand pg 108 PMS6 COST-OF-ILLNESS STUDY OF HIP FRACTURE AMONG KOREAN ELDERLY WOMEN: INCIDENCE-BASED APPROACH Kang HY1, Park SE2, Kang DR3, Kim JY1, Chang YH4, Choi WJ5, Moon SH6, Yang KH6, Park JY7, Kwon SY8, 1Yonsei University, Seoul, South Korea, 2Health Insurance

Review & Assessment Service, Seoul, South Korea, 3Severance Hospital Clinical Trials Center, Seoul, South Korea, 4Department of Public Health, Graduate School, Yonsei University, Seoul, South Korea, 5Health Insurance Review Agency, Seoul, South Korea, 6Department of Orthopedics, College of Medicine, Yonsei University, Seoul, South Korea, 7Konkuk University, Seoul, South Korea, 8The Catholic University of Korea, Seoul, South Korea

pg 108 PMS7 EVALUATION THE FINANCIAL BURDEN OF ILLNESS OF FEMORAL NECK FRACTURE IN CONNECTION WITH COMPLICATION AND FRACTURE TYPE 2 YERS FOL-LOW UP UNDeR 60

Sebestyén A1, Nyárády J2, Tóth F2, Betlehem J2, Vas g2, Boncz I2, 1National Health Insurance Fund Administration, Budapest, Hungary, 2University of Pécs, Pécs, Hungary

pg 108 PMS8 HEALTH RESOURCE UTILIZATION OF OSTEOPOROSIS PATIENTS AT PHRAMONGKUTKLAO HOSPITAL Werayingyong P1, Pongcharoensuk P2, Kamolsilp M3, 1Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand, 2Faculty of Phar-

macy Mahidol University, Ratchathewi, Bangkok, Thailand, 3Phramongkutklao Hospital, Rathavi, Bangkok, Thailand


35






pg 108 PMS9 TOTAL OR PARTIAL KNEE REPLACEMENT? A COST-EFFECTIVENESS ANALYSIS IN PATIENTS WITH KNEE OSTEOARTHRITIS BASED ON TWO-YEAR PRELIMI-NARY DATA

Xie f1, Luo N2, Lo NN3, Lee HP2, 1McMaster University, Hamilton, Ontario, Canada, 2National University of Singapore, Singapore, Singapore, 3Singapore General Hospital, Singapore, Singapore

MUSCULAR-SKELETAL DISORDERS - Patient-Reported Outcomes Studiespg 109 PMS11 MEASURING QUALITY OF LIFE IN PATIENTS WITH FOCAL LOWER LIMB SPASTICITY Halstead M1, Wilson J2, Kovacs G2, Adams J2, Schultz M1, Napier-Flood F3, Rogers J1, 1Allergan Australia, Gordon, NSW, Australia, 2IMS Health, St Leonards,

NSW, Australia, 3Tobermory Scientific Research, St Leonards, NSW, Australia

NeUROLOgIcAL DISORDeRS - cost Studiespg 109 PND1 THE COST OF HOME-BASED CARE FOR THAI ELDERLY WITH DEMENTIA IN A THAI UNIVERSITY HOSPITAL Turongkaravee S1, Chaikledkaew U1, Chansirikarnjana S2, Pongchareonsuk P3, Krairit O2, 1Health Intervention and Technology Assessment Program (HITAP),

Nonthaburi, Thailand, 2Ramathibodi Hospital, Bangkok, Thailand, 3Mahidol University, Bangkok, Thailand

NeUROLOgIcAL DISORDeRS - Patient-Reported Outcomes Studiespg 109 PND2 PReDIcTORS Of MeDIcATION ADHeReNce IN OLDeR ADULTS WITH INSOMNIA Kulkarni AS1, Patel I2, Anderson RT3, Balkrishnan R2, 1Express Scripts Inc, Maryland Heights, MO, USA, 2The Ohio State University, Columbus, OH, USA, 3Wake

Forest University School of Medicine, Winston Salem, NC, USA pg 109 PND4 THE DISEASE BURDEN OF NEUROPATHIC PAIN Huang Y1, Cui L1, Liu G2, Duttagupta S3, Sun F4, 1Chinese Academy of Medical Sciences Peking Union Medical College Hospital, Beijing, China, 2Peking University,

Beijing, China, 3Pfizer Inc, New York, NY, USA, 4Pfizer Investment Co., Limited, Beijing, China

NEUROLOGICAL DISORDERS - Health Care Use & Policy Studiespg 110 PND5 eVALUATINg AN ONLINe fReeWARe cALcULATOR fOR ANALYZINg cOST effecTIVeNeSS DATA fOR fORMULARY DRUg cLASSeS Mcghan W1, Peterson AM2, 1University of the Sciences, Philadelphia, PA, USA, 2University of the Sciences in Philadelphia, Philadelphia, PA, USA

ReSPIRATORY-ReLATeD DISORDeRS - clinical Outcomes Studiespg 110 PRS1 COMPARISON OF EFFECTIVENESS BETWEEN THE PHARMACOTHERAPIES FOR THE SMOKING CESSATION: VARENICLINE, BUPROPION, AND NICOTINE RE-

PLAceMeNT THeRAPY Joe KH1, Kim DJ2, Kim CH3, Bae JY4, Song HJ4, Lee EK4, 1Eulji University, seongnam, kyeonggi, South Korea, 2The catholic university of Korea, Holy family hospital,

Bucheon, South Korea, 3Family Medicine of Seoul Paik Hospital, seoul, South Korea, 4Sook Myung Women’s University, Seoul, South Korea pg 110 PRS2 SMOKING BEHAVIOR AND REASONS FOR SMOKING: A SURVEY OF THAI MALE SMOKERS IN MAJOR CITIES Leartsakulpanitch J, Pfizer (Thailand) Ltd, Bangkok, Thailand pg 110 PRS3 SMOKERS NEED MORE MEDICAL & FAMILY SUPPORT WHEN ATTEMPTING TO QUIT SMOKING Pathan AN, Naqvi SAA, Pfizer Laboratories Limited, Karachi, Sindh, Pakistan pg 111 PRS4 SMOKING EPIDEMIC IN PAKISTAN, A LOOK AT THE TIP OF THE ICEBERG Pathan AN, Naqvi SAA, Pfizer Laboratories Limited, Karachi, Sindh, Pakistan

ReSPIRATORY-ReLATeD DISORDeRS - cost Studiespg 111 PRS5 BUPROPION AND NORTRIPTYLINE IN SMOKING CESSATION: COST-EFFECTIVENESS EVIDENCE IN THAILAND Thavorn K1, Chaiyakunapruk N2, 1University of Toronto, Toronto, Ontario, Canada, 2Naresuan University, Muang, Phitsanulok, Thailandpg 111 PRS6 COST-EFFECTIVENESS ANALYSIS OF SMOKING CESSATION PHARMACOTHERAPIES IN AUSTRALIA Bhatti TA1, Makino K1, Guarnieri C1, Gordois A1, Cotter T2, Perez DA2, Bishop JF2, Glass P2, fong L1, 1IMS Health, St Leonards, New South Wales, Australia, 2Cancer

Institute NSW, Eveleigh, New South Wales, Australia pg 111 PRS7 ecONOMIc eVALUATION Of VAReNIcLINe IN TAIWAN Wen CP1, Wang MT2, Chu CHY3, Sun CC3, Lin SSf3, 1National Health Research Institutes, Zhunan Town, NA, Taiwan, 2National Defense Medical Center, Taipei, NA,

Taiwan, 3Pfizer Taiwan, Taipei County, NA, Taiwanpg 111 PRS8 COST-EFFECTIVENESS EVALUATION OF SYMBICORT®MAINTENANCE AND RELIEVER THERAPY (SMART) COMPARED WITH TRADITIONAL ASTHMA TREAT-

MeNTS fROM THe PeRSPecTIVe Of THAI HeALTH cARe PROVIDeRS Boonsawat W, Khon Kaen University, Khon Kaen, Khon Kaen, Thailandpg 112 PRS9 SMOKING IN THAILAND: A FINANCIAL BURDEN OF KEY SMOKING-RELATED DISEASES Leartsakulpanitch J1, Salole E2, Ngantawee W1, 1Pfizer (Thailand) Ltd, Bangkok, Thailand, 2Pfizer (Australia), Sydney, Australiapg 112 PRS10 ESTIMATING THE ANNUAL COST OF SMOKING-RELATED DISEASES IN INDONESIA Sutrisna B, Surtidewi L, Jusuf A, Hudoyo A, Kusmana D, Setianto B, Indonesia University, Jakarta, Indonesia


36






ReSPIRATORY-ReLATeD DISORDeRS - Patient-Reported Outcomes Studiespg 112 PRS11 cOMPARISON Of TWO UTILITY MeASUReMeNT TecHNIQUeS: TIMe TRADeD Off AND VISUAL ANALOgUe ScALe Natanant S1, Kulpeng W2, Thavorncharoensap M3, Teerawattananon Y3, 1Health Intervention and Technology Assessment Program(HITAP), Muang, Nontaburi,

Thailand, 2Health Intervention and Technology Assessment Program(HITAP), Muang, Nonthaburi, Thailand, 3Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand

RESPIRATORY-RELATED DISORDERS - Health Care Use & Policy Studiespg 112 PRS12 GENDER DISPARITY OF CUTANEOUS HYPERSENSITIVITY REACTION IN U.S. FOOD AND DRUG ADMINISTRATION NEW DRUG APPLICATION REVIEW Lee e1, Johann-Liang R2, 1Howard University School of Pharmacy, Washington, DC, USA, 2U.S. Department of Health and Human Services, Rockville, MD, USApg 113 PRS13 SMOKING AND ASTHMA: THE ADDITIONAL ASTHMA BURDEN ASSOCIATED WITH CURRENT SMOKERS campbell JD, Watanabe JH, Sullivan SD, University of Washington, Seattle, WA, USApg 113 PRS14 MEDICATION PERSISTENCE AND ADHERENCE TO INHALED CORTICOSTEROID TREATMENT AMONG CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS Akazawa M, University of Tokyo, Bunkyo-ku, Tokyo, Japan pg 113 PRS15 GENDER DIFFERENCES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE-RELATED VISITS: BASED ON NAMCS AND NHAMCS FROM 1995-2004 Suh Dc1, Choi IS1, Kim CM2, Nam EW1, Lau H3, 1Rutgers University, Piscataway, NJ, USA, 2Catholic University, Seoul, Suhcho-gu, South Korea, 3Novartis Pharma-

ceuticals, East Hanover, NJ, USApg 113 PRS16 CAN SMOKE-FREE POLICIES BE INTRODUCED IN CHINA? AN APPLICABILITY ASSESSMENT OF EVIDENCE-BASED HEALTH POLICY Hiller Je1, Au N1, Wang S1, Meng Q2, 1University of Adelaide, Adelaide, South Australia, Australia, 2Shandong University China, Jinan, Shandong, China pg 113 PRS17 DOES KEEPING A MEDICAL COST DIARY AFFECT THE MEDICAL UTILIZATION? chae S1, Ko S2, 1Korea Institute for Health and Social Affairs, Seoul, South Korea, 2Pfizer Korea, Seoul, South Korea

SeNSORY SYSTeMS DISORDeRS - cost Studiespg 114 PSS1 ANALYSIS OF COST-UTILITY AND BUDGET IMPACT ON COCHLEAR IMPLANTATION FOR PROFOUNDLY BILATERAL HEARING LOSS PATIENTS IN THAILAND: A

SIMULATION STUDY Kingkaew P1, Werayingyong P1, Youngkong S1, Riewpaiboon W2, Kanchanalarp C3, Tungkeeratichai J3, Potaporn M4, Teerawattananon Y1, 1Health Intervention

and Technology Assessment Program (HITAP), Nonthaburi, Thailand, 2Sirindhorn National Medical Rehablilitation Center, Muang, Nonthaburi, Thailand, 3Rama-thibodi hospital, Ratchathewi, Bangkok, Thailand, 4Rajavithi hospital, Ratchathewi, Bangkok, Thailand

SENSORY SYSTEMS DISORDERS - Health Care Use & Policy Studiespg 114 PSS3 ECONOMIC BURDENT OF ATOPIC MANIFESTATIONS IN PATIENTS WITH ATOPIC DERMATITIS Suh Dc1, Kim CM2, Choi IS1, Sung J3, Huang J1, Gause D4, 1Rutgers University, Piscataway, NJ, USA, 2Catholic University, Seoul, Suhcho-gu, South Korea, 3Novar-

tis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Novartis Pharmaceuticals, East Hanover, NJ, USA pg 114 PSS4 NEEDS ASSESSMENT OF MOTHERS WITH CHILDREN AFFECTED BY DERMATITIS Uras c, Andreoli E, Alfani S, Tabolli S, IDI IRCCS, Rome, Italy

SYSTEMIC DISORDERS/CONDITIONS - Cost Studiespg 114 PSY2 PATHOGEN SAFETY AND THE COST EFFECTIVENESS OF ADVATE IN SOUTH KOREA Epstein JD1, Li-McLeod J1, Bang J2, 1Baxter BioScience, Westlake Village, CA, USA, 2Baxter Healthcare Korea, Seoul, Seoul, South Koreapg 115 PSY3 ecONOMIc eVALUATION Of ORAL cHeLATOR WITH DefeRASIROX VeRSUS INfUSIONAL DefeROXAMINe Kim J, Seoul National University, Seoul, South Korea

SYSTEMIC DISORDERS/CONDITIONS - Patient-Reported Outcomes Studiespg 115 PSY4 HeALTH ReLATeD QUALITY Of LIfe IN PeMPHIgUS Tabolli ST1, Paradisi A2, ferri R3, Di Pietro C1, Abeni D1, Didona B2, Cianchini G2, 1IDI IRCCS, Rome, Italy, 2IDI-IRCCS, Rome, Italy, 3IDI-IRCCS\, Rome, Italy

SYSTEMIC DISORDERS/CONDITIONS - Health Care Use & Policy Studiespg 115 PSY5 PATIENT SELECTION CRITERIA FOR PATIENTS WITH DISCOGENIC LOW BACK PAIN TREATED WITH INTRADISCAL ELECTROTHERMAL THERAPY (IDET): EN-

SURINg APPROPRIATe cARe AND effIcIeNT ReSOURce UTILIZATION Kloth DS1, Fenton DS2, Block JE3, Schultz M4, Rohan B5, 1Connecticut Pain Care, Danbury, CT, USA, 2Mayo Clinic, Jacksonville, FL, USA, 3Jon E Block PhD Inc, San

Francisco, CA, USA, 4Pharmaccess Inc, Westmount, QC, Canada, 5Smith&Nephew Inc, Memphis, TN, USA

URINARY/KIDNEY DISORDERS - Clinical Outcomes Studiespg 115 PUK1 cOMPARINg THe cLINIcAL OUTcOMeS fOLLOWINg URINARY INcONTINeNce TReATMeNT Olah A1, Katona G2, Betlehem J3, Muller A1, Roznar J4, Palfi I1, Cucz P1, Varadyne Horvath A1, Sebestyén A5, Kriszbacher I3, Bódis J3, Vas g3, Boncz I3, 1University of

Pecs, Pecs, Hungary, 2Hospital Baja, Baja, Hungary, 3University of Pécs, Pécs, Hungary, 4University of Pecs, Szombathely, Hungary, 5National Health Insurance Fund Administration, Pecs, Hungary


37






URINARY/KIDNEY DISORDERS - Cost Studiespg 116 PUK2 IN THE UK, AN INCREASED UTILISATION OF PERITONEAL DIALYSIS THERAPY COULD LEAD TO AN INCREASE IN THE NUMBER OF PATIENTS BEING TREATED

FOR RENAL REPLACEMENT THERAPY (RRT) Walker DR1, Sondhi S2, 1Baxter Healthcare Corporation, McGaw Park, IL, USA, 2Baxter Healthcare, Thetford, UKpg 116 PUK3 ECONOMIC IMPACT OF OVERACTIVE BLADDER SYMPTOMS IN JAPAN Inoue S1, Kobayashi M1, Sugaya K2, 1Crecon Research and Consulting Inc, Shibuya-ku, Tokyo, Japan, 2University of the Ryukyus, Nishihara, Okinawa, Japan

URINARY/KIDNEY DISORDERS - Patient-Reported Outcomes Studiespg 116 PUK4 MODeLLINg UTILITY TARIffS fROM A MALAYSIAN PATIeNT POPULATION goh A1, Tan WH2, Aryani Md. Yusof F3, Lim TO3, 1ClinResearch Sdn Bhd, Kuala Lumpur, Malaysia, 2PAREXEL-APEX China, Co., Ltd, Shanghai, China, 3Kuala Lumpur

Hospital, Kuala Lumpur, Malaysia pg 116 PUK5 QUALITY Of LIfe ON DIALYSIS IN MALAYSIA Aryani Md. Yusof F1, goh A2, 1Clinical Research Centre, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia, 2ClinResearch Sdn Bhd, Kuala Lumpur, Malaysia

URINARY/KIDNEY DISORDERS - Health Care Use & Policy Studiespg 117 PUK6 LIBERALISATION OF HEALTH CARE AND ITS IMPACT ON PROVISION, EFFICIENCY AND EQUITY: THE ExPERIENCE OF DIALYSIS IN MALAYSIA Lim TO1, Goh A2, Morad Z3, Mohd Ghazali R4, 1Kuala Lumpur Hospital, Kuala Lumpur, Malaysia, 2ClinResearch Sdn Bhd, Kuala Lumpur, Malaysia, 3International

Medical University, Kuala Lumpur, Malaysia, 4Penang Hospital, Georgetown, Pulau Pinang, Malaysiapg 116 PUK7 DIALYSIS FACILITY CHARACTERISTICS INFLUENCE THE USE OF HOME DIALYSIS IN THE U.S. Walker DR, Inglese GW, Just PM, Baxter Healthcare Corporation, McGaw Park, IL, USA


< A D V E R T I S E M E N T S >

38

ISPOR Promo ad here ?

The mission of ISPOR is to translate pharmacoeconomics and outcomes research into practice to ensure that society allocates scarce health care resources wisely, fairly, and efficiently.

ISPOR has over 4000 members from 97 countries.

The ISPOR Asia Consortium and Latin America Consortium are regional groups within ISPOR that plan and implement educational and scientific initiatives to benefit these regions.

ispor chapters & coNsortia

International Society for Pharmacoeconomics and outcomes research: www.ispor.org

ispor MeMBership

uNitiNg research aNd practice

ispor MeetiNgs

ispor 4th asia-pacific conference

5-7 september 2010 phuket, thailand

Abstract Submission Deadline: 18 March 2010Early Registration Deadline: 20 July 2010

ispor 5th asia-pacific conference

september 2012 singapore


ispor 12th annual european congress

24-27 october 2009 paris, france

Abstract Submission Deadline: 23 June 2009Early Registration Deadline: 8 September 2009


october 2010 prague, czech republic



october 2011 Vienna, austria



8-11 November 2008 athens, greece

Early Registration Deadline: 30 September 2008

ispor 2nd latin america conference

10-12 september 2009 rio de Janeiro, Brazil


ispor 3rd latin america conference

september 2011 México


ispor 13th annual international Meeting

May 3-7, 2008 toronto, oN, canada

Over 1000 presentations! Over 2000 attendees!


May 16-20, 2009 orlando, fl, usa

Abstract Submission Deadline: January 15, 2009Early Registration Deadline: April 7, 2009


May 15-19, 2010 atlanta, ga, usa



May 21-25, 2011 Baltimore, Md, usa


asia-pacific coNfereNces

europeaN coNgresses

latiN aMericaN coNfereNces

North aMericaN MeetiNgs

program and schedule of events – schedule (pdf format)

Documents